{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:42:34Z","timestamp":1793943754942,"version":"4.8.0"},"reference-count":385,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"DOI":"10.1038\/s41390-026-05270-3","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:09:57Z","timestamp":1784308197000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The future of pediatric gene therapy: CRISPR-Cas9, AI, and personalized medicine"],"prefix":"10.1038","author":[{"given":"Yinping","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dexin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihuan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"5270_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02525-0","volume":"17","author":"C von der Lippe","year":"2022","unstructured":"von der Lippe, C., Neteland, I. & Feragen, K. B. Children with a rare congenital genetic disorder: a systematic review of parent experiences. Orphanet J. Rare Dis. 17, 375 (2022).","journal-title":"Orphanet J. Rare Dis."},{"key":"5270_CR2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/nrg3555","volume":"14","author":"KM Boycott","year":"2013","unstructured":"Boycott, K. M., Vanstone, M. R., Bulman, D. E. & MacKenzie, A. E. Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nat. Rev. Genet 14, 681\u2013691 (2013).","journal-title":"Nat. Rev. Genet"},{"key":"5270_CR3","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/ajmg.a.61124","volume":"179","author":"CR Ferreira","year":"2019","unstructured":"Ferreira, C. R. The burden of rare diseases. Am. J. Med. Genet A 179, 885\u2013892 (2019).","journal-title":"Am. J. Med. Genet A"},{"key":"5270_CR4","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/ajmg.a.33380","volume":"152","author":"JS Cohen","year":"2010","unstructured":"Cohen, J. S. & Biesecker, B. B. Quality of life in rare genetic conditions: a systematic review of the literature. Am. J. Med. Genet Part A 152, 1136\u20131156 (2010).","journal-title":"Am. J. Med. Genet Part A"},{"key":"5270_CR5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ijnurstu.2016.07.007","volume":"62","author":"V Waldboth","year":"2016","unstructured":"Waldboth, V., Patch, C., Mahrer-Imhof, R. & Metcalfe, A. Living a normal life in an extraordinary way: A systematic review investigating experiences of families of young people\u2019s transition into adulthood when affected by a genetic and chronic childhood condition. Int. J. Nurs. Stud. 62, 44\u201359 (2016).","journal-title":"Int. J. Nurs. Stud."},{"key":"5270_CR6","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1093\/jpepsy\/jst049","volume":"38","author":"MK Cousino","year":"2013","unstructured":"Cousino, M. K. & Hazen, R. A. Parenting stress among caregivers of children with chronic illness: a systematic review. J. Pediatr. Psychol. 38, 809\u2013828 (2013).","journal-title":"J. Pediatr. Psychol."},{"key":"5270_CR7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/smi.2780","volume":"34","author":"M Pinquart","year":"2018","unstructured":"Pinquart, M. Parenting stress in caregivers of children with chronic physical condition\u2014A meta-analysis. Stress Health 34, 197\u2013207 (2018).","journal-title":"Stress Health"},{"key":"5270_CR8","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.2105\/AJPH.2007.129817","volume":"99","author":"JC Brehaut","year":"2009","unstructured":"Brehaut, J. C. et al. Health among caregivers of children with health problems: findings from a Canadian population-based study. Am. J. Public Health 99, 1254\u20131262 (2009).","journal-title":"Am. J. Public Health"},{"key":"5270_CR9","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/j.1365-2648.2006.03736.x","volume":"53","author":"L Dellve","year":"2006","unstructured":"Dellve, L., Samuelsson, L., Tallborn, A., Fasth, A. & Hallberg, L. R. M. Stress and well-being among parents of children with rare diseases: a prospective intervention study. J. Adv. Nurs. 53, 392\u2013402 (2006).","journal-title":"J. Adv. Nurs."},{"key":"5270_CR10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12875-016-0488-x","volume":"17","author":"LJ Pelentsov","year":"2016","unstructured":"Pelentsov, L. J., Fielder, A. L., Laws, T. A. & Esterman, A. J. The supportive care needs of parents with a child with a rare disease: results of an online survey. BMC Fam. Pract. 17, 88 (2016).","journal-title":"BMC Fam. Pract."},{"key":"5270_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0622-4","volume":"12","author":"Y Zurynski","year":"2017","unstructured":"Zurynski, Y. et al. Australian children living with rare diseases: experiences of diagnosis and perceived consequences of diagnostic delays. Orphanet J. Rare Dis. 12, 68 (2017).","journal-title":"Orphanet J. Rare Dis."},{"key":"5270_CR12","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1111\/jar.12617","volume":"32","author":"C Beighton","year":"2019","unstructured":"Beighton, C. & Wills, J. How parents describe the positive aspects of parenting their child who has intellectual disabilities: a systematic review and narrative synthesis. J. Appl. Res. Intellect. Disabil. 32, 1255\u20131279 (2019).","journal-title":"J. Appl. Res. Intellect. Disabil."},{"key":"5270_CR13","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1073\/pnas.48.12.2026","volume":"48","author":"EH Szybalska","year":"1962","unstructured":"Szybalska, E. H. & Szybalski, W. Genetics of human cell line. IV. DNA-mediated heritable transformation of a biochemical trait. Proc. Natl. Acad. Sci. USA 48, 2026\u20132034 (1962).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"5270_CR14","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","volume":"80","author":"SE Raper","year":"2003","unstructured":"Raper, S. E. et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 80, 148\u2013158 (2003).","journal-title":"Mol. Genet. Metab."},{"key":"5270_CR15","doi-asserted-by":"crossref","unstructured":"Hacein-Bey-Abina S. et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348, 255\u2013256 (2003).","DOI":"10.1056\/NEJM200301163480314"},{"key":"5270_CR16","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/219749a0","volume":"219","author":"S Rogers","year":"1968","unstructured":"Rogers, S. & Pfuderer, P. Use of viruses as carriers of added genetic information. Nature 219, 749\u2013751 (1968).","journal-title":"Nature"},{"key":"5270_CR17","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1126\/science.270.5235.475","volume":"270","author":"RM Blaese","year":"1995","unstructured":"Blaese, R. M. et al. T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science 270, 475\u2013480 (1995).","journal-title":"Science"},{"key":"5270_CR18","first-page":"RA110","volume":"11","author":"R Gardl\u00edk","year":"2005","unstructured":"Gardl\u00edk, R. et al. Vectors and delivery systems in gene therapy. Med. Sci. Monit. 11, RA110\u2013RA121 (2005).","journal-title":"Med. Sci. Monit."},{"key":"5270_CR19","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","volume":"358","author":"AM Maguire","year":"2008","unstructured":"Maguire, A. M. et al. Safety and efficacy of gene transfer for Leber\u2019s congenital amaurosis. N. Engl. J. Med. 358, 2240\u20132248 (2008).","journal-title":"N. Engl. J. Med."},{"key":"5270_CR20","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","volume":"371","author":"AC Nathwani","year":"2014","unstructured":"Nathwani, A. C. et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N. Engl. J. Med. 371, 1994\u20132004 (2014).","journal-title":"N. Engl. J. Med."},{"key":"5270_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1089\/humc.2013.087","volume":"24","author":"LM Bryant","year":"2013","unstructured":"Bryant, L. M. et al. Lessons learned from the clinical development and market authorization of Glybera. Hum. Gene Ther. Clin. Dev. 24, 55\u201364 (2013).","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"5270_CR22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.molmed.2020.12.005","volume":"27","author":"J Dan","year":"2021","unstructured":"Dan, J., Memczak, S. & Izpisua Belmonte, J. C. Expanding the toolbox and targets for gene editing. Trends Mol. Med. 27, 203\u2013206 (2021).","journal-title":"Trends Mol. Med."},{"key":"5270_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.645","volume":"5","author":"F Liu","year":"2024","unstructured":"Liu, F., Li, R., Zhu, Z., Yang, Y. & Lu, F. Current developments of gene therapy in human diseases. MedComm 5, e645 (2024).","journal-title":"MedComm"},{"key":"5270_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.70056","volume":"28","author":"B Cetin","year":"2024","unstructured":"Cetin, B., Erendor, F., Eksi, Y. E., Sanlioglu, A. D. & Sanlioglu, S. Gene and cell therapy of human genetic diseases: Recent advances and future directions. J. Cell Mol. Med. 28, e70056 (2024).","journal-title":"J. Cell Mol. Med."},{"key":"5270_CR25","unstructured":"Administration USF and D. Approved cellular and gene therapy products. Silver Spring, MD US Food Drug Adm. (2022)."},{"key":"5270_CR26","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.csbj.2020.08.031","volume":"18","author":"Y Xu","year":"2020","unstructured":"Xu, Y. & Li, Z. CRISPR-Cas systems: overview, innovations and applications in human disease research and gene therapy. Comput. Struct. Biotechnol. J. 18, 2401\u20132415 (2020).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"5270_CR27","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.mib.2014.07.001","volume":"19","author":"E Charpentier","year":"2014","unstructured":"Charpentier, E. & Marraffini, L. A. Harnessing CRISPR-Cas9 immunity for genetic engineering. Curr. Opin. Microbiol. 19, 114\u2013119 (2014).","journal-title":"Curr. Opin. Microbiol."},{"key":"5270_CR28","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","volume":"157","author":"PD Hsu","year":"2014","unstructured":"Hsu, P. D., Lander, E. S. & Zhang, F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 157, 1262\u20131278 (2014).","journal-title":"Cell"},{"key":"5270_CR29","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1126\/science.aat5011","volume":"361","author":"GJ Knott","year":"2018","unstructured":"Knott, G. J. & Doudna, J. A. CRISPR-Cas guides the future of genetic engineering. Science 361, 866\u2013869 (2018).","journal-title":"Science"},{"key":"5270_CR30","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nm.3793","volume":"21","author":"DBT Cox","year":"2015","unstructured":"Cox, D. B. T., Platt, R. J. & Zhang, F. Therapeutic genome editing: prospects and challenges. Nat. Med. 21, 121\u2013131 (2015).","journal-title":"Nat. Med."},{"key":"5270_CR31","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-biochem-060815-014607","volume":"85","author":"H Wang","year":"2016","unstructured":"Wang, H., La Russa, M. & Qi, L. S. CRISPR\/Cas9 in genome editing and beyond. Annu. Rev. Biochem. 85, 227\u2013264 (2016).","journal-title":"Annu. Rev. Biochem."},{"key":"5270_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cell.2015.12.035","volume":"164","author":"AV Wright","year":"2016","unstructured":"Wright, A. V., Nu\u00f1ez, J. K. & Doudna, J. A. Biology and applications of CRISPR systems: harnessing nature\u2019s toolbox for genome engineering. Cell 164, 29\u201344 (2016).","journal-title":"Cell"},{"key":"5270_CR33","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-phyto-080417-050158","volume":"56","author":"T Langner","year":"2018","unstructured":"Langner, T., Kamoun, S. & Belhaj, K. CRISPR crops: plant genome editing toward disease resistance. Annu. Rev. Phytopathol. 56, 479\u2013512 (2018).","journal-title":"Annu. Rev. Phytopathol."},{"key":"5270_CR34","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/nbt1319","volume":"25","author":"JC Miller","year":"2007","unstructured":"Miller, J. C. et al. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat. Biotechnol. 25, 778\u2013785 (2007).","journal-title":"Nat. Biotechnol."},{"key":"5270_CR35","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1534\/genetics.110.120717","volume":"186","author":"M Christian","year":"2010","unstructured":"Christian, M. et al. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 186, 757\u2013761 (2010).","journal-title":"Genetics"},{"key":"5270_CR36","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev-ecolsys-121415-032428","volume":"47","author":"ER Westra","year":"2016","unstructured":"Westra, E. R., Dowling, A. J., Broniewski, J. M. & van Houte, S. Evolution and ecology of CRISPR. Annu. Rev. Ecol. Evol. Syst. 47, 307\u2013331 (2016).","journal-title":"Annu. Rev. Ecol. Evol. Syst."},{"key":"5270_CR37","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.cell.2017.11.032","volume":"172","author":"F Hille","year":"2018","unstructured":"Hille, F. et al. The biology of CRISPR-Cas: backward and forward. Cell 172, 1239\u20131259 (2018).","journal-title":"Cell"},{"key":"5270_CR38","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.cell.2017.04.005","volume":"169","author":"AC Komor","year":"2017","unstructured":"Komor, A. C., Badran, A. H. & Liu, D. R. CRISPR-based technologies for the manipulation of eukaryotic genomes. Cell 169, 559 (2017).","journal-title":"Cell"},{"key":"5270_CR39","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12934-020-01431-z","volume":"19","author":"Z Liu","year":"2020","unstructured":"Liu, Z., Dong, H., Cui, Y., Cong, L. & Zhang, D. Application of different types of CRISPR\/Cas-based systems in bacteria. Micro. Cell Fact. 19, 172 (2020).","journal-title":"Micro. Cell Fact."},{"key":"5270_CR40","first-page":"353","volume":"15","author":"M Asmamaw","year":"2021","unstructured":"Asmamaw, M. & Zawdie, B. Mechanism and applications of CRISPR\/Cas-9-mediated genome editing. Biologics 15, 353\u2013361 (2021).","journal-title":"Biologics"},{"key":"5270_CR41","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jgg.2016.01.001","volume":"43","author":"Y Mei","year":"2016","unstructured":"Mei, Y., Wang, Y., Chen, H., Sun, Z. S. & Ju, X. D. Recent progress in CRISPR\/Cas9 technology. J. Genet. Genom. 43, 63\u201375 (2016).","journal-title":"J. Genet. Genom."},{"key":"5270_CR42","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","volume":"46","author":"F Jiang","year":"2017","unstructured":"Jiang, F. & Doudna, J. A. CRISPR\u2013Cas9 structures and mechanisms. Annu. Rev. Biophys. 46, 505\u2013529 (2017).","journal-title":"Annu. Rev. Biophys."},{"key":"5270_CR43","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1016\/j.bbamcr.2016.06.009","volume":"1863","author":"SA Ceasar","year":"2016","unstructured":"Ceasar, S. A., Rajan, V., Prykhozhij, S. V., Berman, J. N. & Ignacimuthu, S. Insert, remove or replace: a highly advanced genome editing system using CRISPR\/Cas9. Biochim. Biophys. Acta 1863, 2333\u20132344 (2016).","journal-title":"Biochim. Biophys. Acta"},{"key":"5270_CR44","first-page":"191","volume":"37","author":"M Shao","year":"2016","unstructured":"Shao, M., Xu, T. R. & Chen, C. S. The big bang of genome editing technology: development and application of the CRISPR\/Cas9 system in disease animal models. Dong wu xue yan. jiu = Zool. Res. 37, 191\u2013204 (2016).","journal-title":"jiu = Zool. Res."},{"key":"5270_CR45","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.cell.2014.02.001","volume":"156","author":"H Nishimasu","year":"2014","unstructured":"Nishimasu, H. et al. Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell 156, 935\u2013949 (2014).","journal-title":"Cell"},{"key":"5270_CR46","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40291-019-00392-3","volume":"23","author":"P Papasavva","year":"2019","unstructured":"Papasavva, P., Kleanthous, M. & Lederer, C. W. Rare opportunities: CRISPR\/Cas-based therapy development for rare genetic diseases. Mol. Diagn. Ther. 23, 201\u2013222 (2019).","journal-title":"Mol. Diagn. Ther."},{"key":"5270_CR47","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/pcmedi\/pbab014","volume":"4","author":"W Liu","year":"2021","unstructured":"Liu, W., Li, L., Jiang, J., Wu, M. & Lin, P. Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics. Precis. Clin. Med. 4, 179\u2013191 (2021).","journal-title":"Precis. Clin. Med."},{"key":"5270_CR48","doi-asserted-by":"crossref","unstructured":"Mustafa, M. I. & Makhawi, A. M. SHERLOCK and DETECTR: CRISPR-Cas systems as potential rapid diagnostic tools for emerging infectious diseases. J. Clin. Microbiol. 59, 10\u20131128 (2021).","DOI":"10.1128\/JCM.00745-20"},{"key":"5270_CR49","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1158\/2159-8290.CD-20-1083","volume":"11","author":"SM Fix","year":"2021","unstructured":"Fix, S. M., Jazaeri, A. A. & Hwu, P. Applications of CRISPR genome editing to advance the next generation of adoptive cell therapies for cancer. Cancer Discov. 11, 560\u2013574 (2021).","journal-title":"Cancer Discov."},{"key":"5270_CR50","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.addr.2020.07.015","volume":"158","author":"D Huang","year":"2020","unstructured":"Huang, D., Miller, M., Ashok, B., Jain, S. & Peppas, N. A. CRISPR\/Cas systems to overcome challenges in developing the next generation of T cells for cancer therapy. Adv. Drug Deliv. Rev. 158, 17\u201335 (2020).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"5270_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09693-x","volume":"10","author":"SR Ferdosi","year":"2019","unstructured":"Ferdosi, S. R. et al. Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes. Nat. Commun. 10, 1842 (2019).","journal-title":"Nat. Commun."},{"key":"5270_CR52","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"AV Anzalone","year":"2019","unstructured":"Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149\u2013157 (2019).","journal-title":"Nature"},{"key":"5270_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2021.103060","volume":"60","author":"SH Park","year":"2021","unstructured":"Park, S. H. & Bao, G. CRISPR\/Cas9 gene editing for curing sickle cell disease. Transfus. Apher. Sci. 60, 103060 (2021).","journal-title":"Transfus. Apher. Sci."},{"key":"5270_CR54","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41434-020-0153-9","volume":"28","author":"G Ali","year":"2021","unstructured":"Ali, G., Tariq, M. A., Shahid, K., Ahmad, F. J. & Akram, J. Advances in genome editing: the technology of choice for precise and efficient \u03b2-thalassemia treatment. Gene Ther. 28, 6\u201315 (2021).","journal-title":"Gene Ther."},{"key":"5270_CR55","doi-asserted-by":"crossref","unstructured":"Salisbury-Ruf, C. T. & Larochelle, A. Advances and obstacles in homology-mediated gene editing of hematopoietic stem cells. J. Clin. Med. 10, 513 (2021).","DOI":"10.3390\/jcm10030513"},{"key":"5270_CR56","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/13816810.2021.1904421","volume":"42","author":"M Bansal","year":"2021","unstructured":"Bansal, M. et al. CRISPR Cas9 based genome editing in inherited retinal dystrophies. Ophthalmic Genet. 42, 365\u2013374 (2021).","journal-title":"Ophthalmic Genet."},{"key":"5270_CR57","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1001\/jamaophthalmol.2020.6418","volume":"139","author":"LE Fry","year":"2021","unstructured":"Fry, L. E., McClements, M. E. & MacLaren, R. E. Analysis of pathogenic variants correctable with CRISPR base editing among patients with recessive inherited retinal degeneration. JAMA Ophthalmol. 139, 319\u2013328 (2021).","journal-title":"JAMA Ophthalmol."},{"key":"5270_CR58","doi-asserted-by":"publisher","first-page":"838","DOI":"10.3389\/fnins.2020.00838","volume":"14","author":"C Gallego","year":"2020","unstructured":"Gallego, C., Gon\u00e7alves, M. A. F. V. & Wijnholds, J. Novel therapeutic approaches for the treatment of retinal degenerative diseases: focus on CRISPR\/Cas-based gene editing. Front. Neurosci. 14, 838 (2020).","journal-title":"Front. Neurosci."},{"key":"5270_CR59","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/s41434-021-00222-4","volume":"28","author":"C Kupatt","year":"2021","unstructured":"Kupatt, C. et al. Genome editing for Duchenne muscular dystrophy: a glimpse of the future? Gene Ther. 28, 542\u2013548 (2021).","journal-title":"Gene Ther."},{"key":"5270_CR60","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/s41431-021-00811-2","volume":"29","author":"V Himi\u010d","year":"2021","unstructured":"Himi\u010d, V. & Davies, K. E. Evaluating the potential of novel genetic approaches for the treatment of Duchenne muscular dystrophy. Eur. J. Hum. Genet. 29, 1369\u20131376 (2021).","journal-title":"Eur. J. Hum. Genet."},{"key":"5270_CR61","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1016\/j.ymthe.2021.04.002","volume":"29","author":"E Choi","year":"2021","unstructured":"Choi, E. & Koo, T. CRISPR technologies for the treatment of Duchenne muscular dystrophy. Mol. Ther. 29, 3179\u20133191 (2021).","journal-title":"Mol. Ther."},{"key":"5270_CR62","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.ymthe.2020.11.023","volume":"29","author":"N Li","year":"2021","unstructured":"Li, N. et al. CRISPR\/Cas9-mediated gene correction in newborn rabbits with hereditary tyrosinemia type I. Mol. Ther. 29, 1001\u20131015 (2021).","journal-title":"Mol. Ther."},{"key":"5270_CR63","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1089\/hum.2020.042","volume":"32","author":"QS Zhang","year":"2021","unstructured":"Zhang, Q. S. et al. Induced liver regeneration enhances CRISPR\/Cas9-mediated gene repair in tyrosinemia type 1. Hum. Gene Ther. 32, 294\u2013301 (2021).","journal-title":"Hum. Gene Ther."},{"key":"5270_CR64","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1165\/rcmb.2020-0159PS","volume":"63","author":"R Lorincz","year":"2020","unstructured":"Lorincz, R. & Curiel, D. T. Advances in Alpha-1 antitrypsin gene therapy. Am. J. Respir. Cell Mol. Biol. 63, 560\u2013570 (2020).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"5270_CR65","doi-asserted-by":"crossref","unstructured":"Alapati, D. et al. In utero gene editing for monogenic lung disease. Sci Transl. Med. 11, eaav8375 (2019).","DOI":"10.1126\/scitranslmed.aav8375"},{"key":"5270_CR66","doi-asserted-by":"crossref","unstructured":"Maule, G., Arosio, D. & Cereseto, A. Gene therapy for cystic fibrosis: progress and challenges of genome editing. Int. J. Mol Sci. 21, 3903 (2020).","DOI":"10.3390\/ijms21113903"},{"key":"5270_CR67","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.addr.2020.06.001","volume":"168","author":"MYT Chow","year":"2021","unstructured":"Chow, M. Y. T., Chang, R. Y. K. & Chan, H. K. Inhalation delivery technology for genome-editing of respiratory diseases. Adv. Drug Deliv. Rev. 168, 217\u2013228 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"5270_CR68","doi-asserted-by":"crossref","unstructured":"Hanafy, A. S., Schoch, S. & Lamprecht, A. CRISPR\/Cas9 delivery potentials in alzheimer\u2019s disease management: a mini review. Pharmaceutics 12, 801 (2020).","DOI":"10.3390\/pharmaceutics12090801"},{"key":"5270_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118165","volume":"259","author":"A Karimian","year":"2020","unstructured":"Karimian, A. et al. CRISPR\/Cas9 novel therapeutic road for the treatment of neurodegenerative diseases. Life Sci. 259, 118165 (2020).","journal-title":"Life Sci."},{"key":"5270_CR70","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1002\/jnr.24845","volume":"99","author":"M Beatriz","year":"2021","unstructured":"Beatriz, M., Lopes, C., Ribeiro, A. C. S. & Rego, A. C. C. Revisiting cell and gene therapies in Huntington\u2019s disease. J. Neurosci. Res. 99, 1744\u20131762 (2021).","journal-title":"J. Neurosci. Res."},{"key":"5270_CR71","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.addr.2020.05.001","volume":"168","author":"N Ding","year":"2021","unstructured":"Ding, N., Lee, S., Lieber-Kotz, M., Yang, J. & Gao, X. Advances in genome editing for genetic hearing loss. Adv. Drug Deliv. Rev. 168, 118\u2013133 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"5270_CR72","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s13353-019-00535-6","volume":"61","author":"R Farooq","year":"2020","unstructured":"Farooq, R., Hussain, K., Tariq, M., Farooq, A. & Mustafa, M. CRISPR\/Cas9: targeted genome editing for the treatment of hereditary hearing loss. J. Appl. Genet. 61, 51\u201365 (2020).","journal-title":"J. Appl. Genet."},{"key":"5270_CR73","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1002\/iub.2296","volume":"72","author":"I Mohammadzadeh","year":"2020","unstructured":"Mohammadzadeh, I. et al. CRISPR\/Cas9 gene editing: a new therapeutic approach in the treatment of infection and autoimmunity. IUBMB Life 72, 1603\u20131621 (2020).","journal-title":"IUBMB Life"},{"key":"5270_CR74","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.bulcan.2020.01.001","volume":"107","author":"B Abbar","year":"2020","unstructured":"Abbar, B., Veyri, M., Solas, C., Poizot-Martin, I. & Spano, J. P. [HIV and cancer: Update 2020]. Bull. Cancer 107, 21\u201329 (2020).","journal-title":"Bull. Cancer"},{"key":"5270_CR75","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1089\/hum.2018.018","volume":"29","author":"L Yin","year":"2018","unstructured":"Yin, L. et al. CRISPR\/Cas9 inhibits multiple steps of HIV-1 infection. Hum. Gene Ther. 29, 1264\u20131276 (2018).","journal-title":"Hum. Gene Ther."},{"key":"5270_CR76","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3389\/fcimb.2019.00069","volume":"9","author":"Q Xiao","year":"2019","unstructured":"Xiao, Q., Guo, D. & Chen, S. Application of CRISPR\/Cas9-based gene editing in HIV-1\/AIDS therapy. Front. Cell Infect. Microbiol. 9, 69 (2019).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"5270_CR77","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.coviro.2019.07.001","volume":"38","author":"AT Das","year":"2019","unstructured":"Das, A. T., Binda, C. S. & Berkhout, B. Elimination of infectious HIV DNA by CRISPR-Cas9. Curr. Opin. Virol. 38, 81\u201388 (2019).","journal-title":"Curr. Opin. Virol."},{"key":"5270_CR78","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.3389\/fmicb.2020.01872","volume":"11","author":"NT Sullivan","year":"2020","unstructured":"Sullivan, N. T. et al. Designing safer CRISPR\/Cas9 therapeutics for hiv: defining factors that regulate and technologies used to detect off-target editing. Front. Microbiol. 11, 1872 (2020).","journal-title":"Front. Microbiol."},{"key":"5270_CR79","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.omtn.2020.05.030","volume":"21","author":"L Yin","year":"2020","unstructured":"Yin, L. et al. CRISPR-Cas13a inhibits HIV-1 infection. Mol. Ther. Nucleic Acids 21, 147\u2013155 (2020).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"5270_CR80","doi-asserted-by":"publisher","first-page":"5527","DOI":"10.1093\/nar\/gkaa226","volume":"48","author":"Z Gao","year":"2020","unstructured":"Gao, Z., Fan, M., Das, A. T., Herrera-Carrillo, E. & Berkhout, B. Extinction of all infectious HIV in cell culture by the CRISPR-Cas12a system with only a single crRNA. Nucleic Acids Res. 48, 5527\u20135539 (2020).","journal-title":"Nucleic Acids Res."},{"key":"5270_CR81","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41417-019-0116-8","volume":"27","author":"J Nair","year":"2020","unstructured":"Nair, J., Nair, A., Veerappan, S. & Sen, D. Translatable gene therapy for lung cancer using CRISPR-CAS9-an exploratory review. Cancer Gene Ther. 27, 116\u201324 (2020).","journal-title":"Cancer Gene Ther."},{"key":"5270_CR82","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201700964","volume":"5","author":"Y Chen","year":"2018","unstructured":"Chen, Y. & Zhang, Y. Application of the CRISPR\/Cas9 system to drug resistance in breast cancer. Adv. Sci. 5, 1700964 (2018).","journal-title":"Adv. Sci."},{"key":"5270_CR83","doi-asserted-by":"publisher","first-page":"219","DOI":"10.7150\/jca.22554","volume":"9","author":"H Yang","year":"2018","unstructured":"Yang, H. et al. Break breast cancer addiction by CRISPR\/Cas9 genome editing. J. Cancer 9, 219\u2013231 (2018).","journal-title":"J. Cancer"},{"key":"5270_CR84","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s12094-020-02450-3","volume":"23","author":"Z Liu","year":"2021","unstructured":"Liu, Z. et al. Research on CRISPR\/system in major cancers and its potential in cancer treatments. Clin. Transl. Oncol. 23, 425\u2013433 (2021).","journal-title":"Clin. Transl. Oncol."},{"key":"5270_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118525","volume":"263","author":"A Hazafa","year":"2020","unstructured":"Hazafa, A. et al. CRISPR\/Cas9: a powerful genome editing technique for the treatment of cancer cells with present challenges and future directions. Life Sci. 263, 118525 (2020).","journal-title":"Life Sci."},{"key":"5270_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.111007","volume":"133","author":"M Zhang","year":"2021","unstructured":"Zhang, M., Eshraghian, E. A., Jammal, O. A. L., Zhang, Z. & Zhu, X. CRISPR technology: the engine that drives cancer therapy. Biomed. Pharmacother. 133, 111007 (2021).","journal-title":"Biomed. Pharmacother."},{"key":"5270_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-020-02118-9","volume":"21","author":"I Noorani","year":"2020","unstructured":"Noorani, I., Bradley, A. & de la Rosa, J. CRISPR and transposon in vivo screens for cancer drivers and therapeutic targets. Genome Biol. 21, 204 (2020).","journal-title":"Genome Biol."},{"key":"5270_CR88","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41401-019-0322-9","volume":"41","author":"H Xing","year":"2020","unstructured":"Xing, H. & Meng, L. H. CRISPR-cas9: a powerful tool towards precision medicine in cancer treatment. Acta Pharm. Sin. 41, 583\u2013587 (2020).","journal-title":"Acta Pharm. Sin."},{"key":"5270_CR89","doi-asserted-by":"publisher","DOI":"10.1007\/s13205-021-02680-4","volume":"11","author":"N Siva","year":"2021","unstructured":"Siva, N. et al. Genome-editing approaches and applications: a brief review on CRISPR technology and its role in cancer. 3 Biotech 11, 146 (2021).","journal-title":"3 Biotech"},{"key":"5270_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2025.149257","volume":"942","author":"H Harris","year":"2025","unstructured":"Harris, H. & Kittur, J. Unlocking the potential of CRISPR-Cas9 for cystic fibrosis: a systematic literature review. Gene 942, 149257 (2025).","journal-title":"Gene"},{"key":"5270_CR91","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1016\/j.ymthe.2024.07.015","volume":"32","author":"G Frati","year":"2024","unstructured":"Frati, G. et al. Safety and efficacy studies of CRISPR-Cas9 treatment of sickle cell disease highlights disease-specific responses. Mol. Ther. 32, 4337\u20134352 (2024).","journal-title":"Mol. Ther."},{"key":"5270_CR92","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nature.2016.20988","volume":"539","author":"D Cyranoski","year":"2016","unstructured":"Cyranoski, D. CRISPR gene-editing tested in a person for the first time. Nature 539, 479 (2016).","journal-title":"Nature"},{"key":"5270_CR93","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.stem.2024.04.021","volume":"31","author":"S Li","year":"2024","unstructured":"Li, S. et al. Modified lentiviral globin gene therapy for pediatric \u03b2(0)\/\u03b2(0) transfusion-dependent \u03b2-thalassemia: a single-center, single-arm pilot trial. Cell Stem Cell 31, 961\u2013973.e8 (2024).","journal-title":"Cell Stem Cell"},{"key":"5270_CR94","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1016\/j.ymthe.2017.04.027","volume":"25","author":"L Xu","year":"2017","unstructured":"Xu, L. et al. CRISPR\/Cas9-mediated CCR5 ablation in human hematopoietic stem\/progenitor cells confers HIV-1 resistance in vivo. Mol. Ther. 25, 1782\u20131789 (2017).","journal-title":"Mol. Ther."},{"key":"5270_CR95","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1056\/NEJMoa1817426","volume":"381","author":"L Xu","year":"2019","unstructured":"Xu, L. et al. CRISPR-edited stem cells in a patient with hiv and acute lymphocytic leukemia. N. Engl. J. Med. 381, 1240\u20131247 (2019).","journal-title":"N. Engl. J. Med."},{"key":"5270_CR96","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1089\/hum.2021.013","volume":"32","author":"I Dasgupta","year":"2021","unstructured":"Dasgupta, I., Flotte, T. R. & Keeler, A. M. CRISPR\/Cas-dependent and nuclease-free in vivo therapeutic gene editing. Hum. Gene Ther. 32, 275\u2013293 (2021).","journal-title":"Hum. Gene Ther."},{"key":"5270_CR97","doi-asserted-by":"crossref","unstructured":"Ledford, H. CRISPR treatment inserted directly into the body for first time. Nature 579, 185 (2020).","DOI":"10.1038\/d41586-020-00655-8"},{"key":"5270_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1364135","volume":"15","author":"F Xu","year":"2024","unstructured":"Xu, F. et al. Breaking genetic shackles: the advance of base editing in genetic disorder treatment. Front. Pharm. 15, 1364135 (2024).","journal-title":"Front. Pharm."},{"key":"5270_CR99","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","volume":"533","author":"AC Komor","year":"2016","unstructured":"Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 420\u2013424 (2016).","journal-title":"Nature"},{"key":"5270_CR100","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nature24644","volume":"551","author":"NM Gaudelli","year":"2017","unstructured":"Gaudelli, N. M. et al. Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage. Nature 551, 464\u2013471 (2017).","journal-title":"Nature"},{"key":"5270_CR101","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek, M. et al. A programmable dual-RNA\u2013guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816\u2013821 (2012).","journal-title":"Science"},{"key":"5270_CR102","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00018-009-8739-9","volume":"66","author":"C Kunz","year":"2009","unstructured":"Kunz, C., Saito, Y. & Sch\u00e4r, P. DNA Repair in mammalian cells: mismatched repair: variations on a theme. Cell Mol. Life Sci. 66, 1021\u20131038 (2009).","journal-title":"Cell Mol. Life Sci."},{"key":"5270_CR103","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/S1097-2765(02)00742-6","volume":"10","author":"RS Harris","year":"2002","unstructured":"Harris, R. S., Petersen-Mahrt, S. K. & Neuberger, M. S. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol. Cell 10, 1247\u20131253 (2002).","journal-title":"Mol. Cell"},{"key":"5270_CR104","doi-asserted-by":"publisher","first-page":"8298","DOI":"10.1073\/pnas.92.18.8298","volume":"92","author":"TM Woolf","year":"1995","unstructured":"Woolf, T. M., Chase, J. M. & Stinchcomb, D. T. Toward the therapeutic editing of mutated RNA sequences. Proc. Natl. Acad. Sci. USA 92, 8298\u20138302 (1995).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"5270_CR105","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-biochem-060208-105251","volume":"79","author":"K Nishikura","year":"2010","unstructured":"Nishikura, K. Functions and regulation of RNA editing by ADAR deaminases. Annu. Rev. Biochem. 79, 321\u2013349 (2010).","journal-title":"Annu. Rev. Biochem."},{"key":"5270_CR106","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1006\/meth.1998.0605","volume":"15","author":"MA O\u2019Connell","year":"1998","unstructured":"O\u2019Connell, M. A., Gerber, A. & Keegan, L. P. Purification of native and recombinant double-stranded RNA-specific adenosine deaminases. Methods 15, 51\u201362 (1998).","journal-title":"Methods"},{"key":"5270_CR107","doi-asserted-by":"publisher","first-page":"6267","DOI":"10.1002\/anie.201402634","volume":"53","author":"P Vogel","year":"2014","unstructured":"Vogel, P., Schneider, M. F., Wettengel, J. & Stafforst, T. Improving site-directed RNA editing in vitro and in cell culture by chemical modification of the guideRNA. Angew. Chem. Int. Ed. Engl. 53, 6267\u20136271 (2014).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"5270_CR108","doi-asserted-by":"publisher","first-page":"18285","DOI":"10.1073\/pnas.1306243110","volume":"110","author":"MF Montiel-Gonzalez","year":"2013","unstructured":"Montiel-Gonzalez, M. F., Vallecillo-Viejo, I., Yudowski, G. A. & Rosenthal, J. J. C. Correction of mutations within the cystic fibrosis transmembrane conductance regulator by site-directed RNA editing. Proc. Natl. Acad. Sci. USA 110, 18285\u201318290 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"5270_CR109","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/s41587-019-0178-z","volume":"37","author":"L Qu","year":"2019","unstructured":"Qu, L. et al. Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs. Nat. Biotechnol. 37, 1059\u20131069 (2019).","journal-title":"Nat. Biotechnol."},{"key":"5270_CR110","first-page":"2797","volume":"45","author":"J Wettengel","year":"2017","unstructured":"Wettengel, J., Reautschnig, P., Geisler, S., Kahle, P. J. & Stafforst, T. Harnessing human ADAR2 for RNA repair - Recoding a PINK1 mutation rescues mitophagy. Nucleic Acids Res. 45, 2797\u20132808 (2017).","journal-title":"Nucleic Acids Res."},{"key":"5270_CR111","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/tpj.13899","volume":"94","author":"F Wolter","year":"2018","unstructured":"Wolter, F. & Puchta, H. The CRISPR\/Cas revolution reaches the RNA world: Cas13, a new Swiss Army knife for plant biologists. Plant J. 94, 767\u2013775 (2018).","journal-title":"Plant J."},{"key":"5270_CR112","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1126\/science.aaq0180","volume":"358","author":"DBT Cox","year":"2017","unstructured":"Cox, D. B. T. et al. RNA editing with CRISPR-Cas13. Science 358, 1019\u20131027 (2017).","journal-title":"Science"},{"key":"5270_CR113","doi-asserted-by":"publisher","first-page":"e13808","DOI":"10.1111\/cpr.13808","volume":"58","author":"M Li","year":"2025","unstructured":"Li, M., Lin, Y., Cheng, Q. & Wei, T. Prime Editing: a revolutionary technology for precise treatment of genetic disorders. Cell Prolif. 58, e13808 (2025).","journal-title":"Cell Prolif."},{"key":"5270_CR114","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.1016\/j.cell.2021.09.018","volume":"184","author":"PJ Chen","year":"2021","unstructured":"Chen, P. J. et al. Enhanced prime editing systems by manipulating cellular determinants of editing outcomes. Cell 184, 5635\u20135652.e29 (2021).","journal-title":"Cell"},{"key":"5270_CR115","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1038\/s41596-022-00724-4","volume":"17","author":"JL Doman","year":"2022","unstructured":"Doman, J. L., Sousa, A. A., Randolph, P. B., Chen, P. J. & Liu, D. R. Designing and executing prime editing experiments in mammalian cells. Nat. Protoc. 17, 2431\u20132468 (2022).","journal-title":"Nat. Protoc."},{"key":"5270_CR116","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22295-w","volume":"12","author":"P Liu","year":"2021","unstructured":"Liu, P. et al. Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice. Nat. Commun. 12, 2121 (2021).","journal-title":"Nat. Commun."},{"key":"5270_CR117","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/j.stem.2021.04.010","volume":"28","author":"Y Kim","year":"2021","unstructured":"Kim, Y. et al. Adenine base editing and prime editing of chemically derived hepatic progenitors rescue genetic liver disease. Cell Stem Cell 28, 1614\u20131624.e5 (2021).","journal-title":"Cell Stem Cell"},{"key":"5270_CR118","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/0092-8674(93)90331-J","volume":"75","author":"R Parsons","year":"1993","unstructured":"Parsons, R. et al. Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell 75, 1227\u20131236 (1993).","journal-title":"Cell"},{"key":"5270_CR119","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1016\/j.cell.2023.07.039","volume":"186","author":"JL Doman","year":"2023","unstructured":"Doman, J. L. et al. Phage-assisted evolution and protein engineering yield compact, efficient prime editors. Cell 186, 3983\u20134002.e26 (2023).","journal-title":"Cell"},{"key":"5270_CR120","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41586-024-07259-6","volume":"628","author":"J Yan","year":"2024","unstructured":"Yan, J. et al. Improving prime editing with an endogenous small RNA-binding protein. Nature 628, 639\u2013647 (2024).","journal-title":"Nature"},{"key":"5270_CR121","doi-asserted-by":"crossref","unstructured":"Maeshima, K., Iida, S. & Tamura, S. Physical nature of chromatin in the nucleus. Cold Spring Harb. Perspect. Biol. 13, a040675 (2021).","DOI":"10.1101\/cshperspect.a040675"},{"key":"5270_CR122","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nrg2752","volume":"11","author":"R Margueron","year":"2010","unstructured":"Margueron, R. & Reinberg, D. Chromatin structure and the inheritance of epigenetic information. Nat. Rev. Genet 11, 285\u2013296 (2010).","journal-title":"Nat. Rev. Genet"},{"key":"5270_CR123","doi-asserted-by":"publisher","first-page":"a003889","DOI":"10.1101\/cshperspect.a003889","volume":"2","author":"T Cremer","year":"2010","unstructured":"Cremer, T. & Cremer, M. Chromosome territories. Cold Spring Harb. Perspect. Biol. 2, a003889 (2010).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"5270_CR124","doi-asserted-by":"crossref","unstructured":"Ueda, J., Yamazaki, T. & Funakoshi, H. Toward the development of epigenome editing-based therapeutics: potentials and challenges. Int. J. Mol. Sci. 24, 4778 (2023).","DOI":"10.3390\/ijms24054778"},{"key":"5270_CR125","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.bbagen.2008.12.006","volume":"1790","author":"A Lennartsson","year":"2009","unstructured":"Lennartsson, A. & Ekwall, K. Histone modification patterns and epigenetic codes. Biochim. Biophys. Acta 1790, 863\u2013868 (2009).","journal-title":"Biochim. Biophys. Acta"},{"key":"5270_CR126","doi-asserted-by":"publisher","first-page":"a025064","DOI":"10.1101\/cshperspect.a025064","volume":"7","author":"Y Zhao","year":"2015","unstructured":"Zhao, Y. & Garcia, B. A. Comprehensive catalog of currently documented histone modifications. Cold Spring Harb. Perspect. Biol. 7, a025064 (2015).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"5270_CR127","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrg.2016.59","volume":"17","author":"CD Allis","year":"2016","unstructured":"Allis, C. D. & Jenuwein, T. The molecular hallmarks of epigenetic control. Nat. Rev. Genet. 17, 487\u2013500 (2016).","journal-title":"Nat. Rev. Genet."},{"key":"5270_CR128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jmb.2009.10.031","volume":"395","author":"PR Cook","year":"2010","unstructured":"Cook, P. R. A model for all genomes: the role of transcription factories. J. Mol. Biol. 395, 1\u201310 (2010).","journal-title":"J. Mol. Biol."},{"key":"5270_CR129","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/nrm1761","volume":"6","author":"C Martin","year":"2005","unstructured":"Martin, C. & Zhang, Y. The diverse functions of histone lysine methylation. Nat. Rev. Mol. Cell Biol. 6, 838\u2013849 (2005).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"5270_CR130","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.molcel.2012.11.006","volume":"48","author":"JC Black","year":"2012","unstructured":"Black, J. C., Van Rechem, C. & Whetstine, J. R. Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol. Cell 48, 491\u2013507 (2012).","journal-title":"Mol. Cell"},{"key":"5270_CR131","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2017.11","volume":"49","author":"K Hyun","year":"2017","unstructured":"Hyun, K., Jeon, J., Park, K. & Kim, J. Writing, erasing and reading histone lysine methylations. Exp. Mol. Med. 49, e324 (2017).","journal-title":"Exp. Mol. Med."},{"key":"5270_CR132","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/nsmb.2436","volume":"19","author":"CA Musselman","year":"2012","unstructured":"Musselman, C. A., Lalonde, M. E., C\u00f4t\u00e9, J. & Kutateladze, T. G. Perceiving the epigenetic landscape through histone readers. Nat. Struct. Mol. Biol. 19, 1218\u20131227 (2012).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"5270_CR133","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/sj.embor.7400625","volume":"7","author":"J Kim","year":"2006","unstructured":"Kim, J. et al. Tudor, MBT and chromo domains gauge the degree of lysine methylation. EMBO Rep. 7, 397\u2013403 (2006).","journal-title":"EMBO Rep."},{"key":"5270_CR134","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nature22989","volume":"547","author":"AR Strom","year":"2017","unstructured":"Strom, A. R. et al. Phase separation drives heterochromatin domain formation. Nature 547, 241\u2013245 (2017).","journal-title":"Nature"},{"key":"5270_CR135","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/nature22822","volume":"547","author":"AG Larson","year":"2017","unstructured":"Larson, A. G. et al. Liquid droplet formation by HP1\u03b1 suggests a role for phase separation in heterochromatin. Nature 547, 236\u2013240 (2017).","journal-title":"Nature"},{"key":"5270_CR136","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1038\/sj.mt.6300345","volume":"15","author":"TI Cornu","year":"2007","unstructured":"Cornu, T. I. & Cathomen, T. Targeted genome modifications using integrase-deficient lentiviral vectors. Mol. Ther. 15, 2107\u20132113 (2007).","journal-title":"Mol. Ther."},{"key":"5270_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102457","volume":"36","author":"A Cavazza","year":"2025","unstructured":"Cavazza, A. et al. Advanced delivery systems for gene editing: a comprehensive review from the GenE-HumDi COST Action Working Group. Mol. Ther. Nucleic Acids 36, 102457 (2025).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"5270_CR138","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/gt.2014.20","volume":"21","author":"J Riviere","year":"2014","unstructured":"Riviere, J. et al. Variable correction of Artemis deficiency by I-Sce1-meganuclease-assisted homologous recombination in murine hematopoietic stem cells. Gene Ther. 21, 529\u2013532 (2014).","journal-title":"Gene Ther."},{"key":"5270_CR139","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/nbt1353","volume":"25","author":"A Lombardo","year":"2007","unstructured":"Lombardo, A. et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat. Biotechnol. 25, 1298\u20131306 (2007).","journal-title":"Nat. Biotechnol."},{"key":"5270_CR140","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1038\/mt.2013.143","volume":"21","author":"A Coluccio","year":"2013","unstructured":"Coluccio, A. et al. Targeted gene addition in human epithelial stem cells by zinc-finger nuclease-mediated homologous recombination. Mol. Ther. 21, 1695\u20131704 (2013).","journal-title":"Mol. Ther."},{"key":"5270_CR141","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1038\/mt.2013.106","volume":"21","author":"AV Joglekar","year":"2013","unstructured":"Joglekar, A. V. et al. Integrase-defective lentiviral vectors as a delivery platform for targeted modification of adenosine deaminase locus. Mol. Ther. 21, 1705\u20131717 (2013).","journal-title":"Mol. Ther."},{"key":"5270_CR142","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1089\/hum.2017.047","volume":"29","author":"A Gutierrez-Guerrero","year":"2018","unstructured":"Gutierrez-Guerrero, A. et al. Comparison of zinc finger nucleases versus CRISPR-specific nucleases for genome editing of the Wiskott-Aldrich syndrome locus. Hum. Gene Ther. 29, 366\u2013380 (2018).","journal-title":"Hum. Gene Ther."},{"key":"5270_CR143","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.omtn.2018.08.007","volume":"13","author":"S S\u00e1nchez-Hern\u00e1ndez","year":"2018","unstructured":"S\u00e1nchez-Hern\u00e1ndez, S. et al. The IS2 element improves transcription efficiency of integration-deficient lentiviral vector episomes. Mol. Ther. Acids 13, 16\u201328 (2018).","journal-title":"Mol. Ther. Acids"},{"key":"5270_CR144","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1089\/hgtb.2013.107","volume":"24","author":"LPL Pelascini","year":"2013","unstructured":"Pelascini, L. P. L. et al. Histone deacetylase inhibition rescues gene knockout levels achieved with integrase-defective lentiviral vectors encoding zinc-finger nucleases. Hum. Gene Ther. Methods 24, 399\u2013411 (2013).","journal-title":"Hum. Gene Ther. Methods"},{"key":"5270_CR145","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.omtm.2017.04.002","volume":"5","author":"PI Ortinski","year":"2017","unstructured":"Ortinski, P. I., O\u2019Donovan, B., Dong, X. & Kantor, B. Integrase-deficient lentiviral vector as an all-in-one platform for highly efficient CRISPR\/Cas9-mediated gene editing. Mol. Ther. Methods Clin. Dev. 5, 153\u2013164 (2017).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"5270_CR146","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.omtm.2021.02.022","volume":"21","author":"N Uchida","year":"2021","unstructured":"Uchida, N. et al. Cas9 protein delivery non-integrating lentiviral vectors for gene correction in sickle cell disease. Mol. Ther. Methods Clin. Dev. 21, 121\u2013132 (2021).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"5270_CR147","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.stem.2022.09.001","volume":"29","author":"S Ferrari","year":"2022","unstructured":"Ferrari, S. et al. Choice of template delivery mitigates the genotoxic risk and adverse impact of editing in human hematopoietic stem cells. Cell Stem Cell 29, 1428\u20131444 (2022).","journal-title":"Cell Stem Cell"},{"key":"5270_CR148","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.omtm.2023.08.020","volume":"30","author":"C Asperti","year":"2023","unstructured":"Asperti, C. et al. Scalable GMP-compliant gene correction of CD4+ T cells with IDLV template functionally validated in vitro and in vivo. Mol. Ther. Methods Clin. Dev. 30, 546\u2013557 (2023).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"5270_CR149","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3390\/life10120366","volume":"10","author":"P Lyu","year":"2020","unstructured":"Lyu, P., Wang, L. & Lu, B. Virus-like particle mediated CRISPR\/Cas9 delivery for efficient and safe genome editing. Life 10, 366 (2020).","journal-title":"Life"},{"key":"5270_CR150","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1038\/s41587-023-02078-y","volume":"42","author":"M An","year":"2024","unstructured":"An, M. et al. Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in vivo. Nat. Biotechnol. 42, 1526\u20131537 (2024).","journal-title":"Nat. Biotechnol."},{"key":"5270_CR151","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","volume":"185","author":"S Banskota","year":"2022","unstructured":"Banskota, S. et al. Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell 185, 250\u2013265 (2022).","journal-title":"Cell"},{"key":"5270_CR152","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1126\/science.abg6155","volume":"373","author":"M Segel","year":"2021","unstructured":"Segel, M. et al. Mammalian retrovirus-like protein PEG10 packages its own mRNA and can be pseudotyped for mRNA delivery. Science 373, 882\u2013889 (2021).","journal-title":"Science"},{"key":"5270_CR153","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/gt.2016.27","volume":"23","author":"JG Choi","year":"2016","unstructured":"Choi, J. G. et al. Lentivirus pre-packed with Cas9 protein for safer gene editing. Gene Ther. 23, 627\u2013633 (2016).","journal-title":"Gene Ther."},{"key":"5270_CR154","doi-asserted-by":"crossref","unstructured":"Hamilton, J. R. et al. Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering. Cell Rep. 35, (2021).","DOI":"10.1016\/j.celrep.2021.109207"},{"key":"5270_CR155","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s43246-022-00229-3","volume":"3","author":"AP Biela","year":"2022","unstructured":"Biela, A. P., Naskalska, A., Fatehi, F., Twarock, R. & Heddle, J. G. Programmable polymorphism of a virus-like particle. Commun. Mater. 3, 7 (2022).","journal-title":"Commun. Mater."},{"key":"5270_CR156","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1089\/hum.2024.105","volume":"35","author":"JH Janns","year":"2024","unstructured":"Janns, J. H. & Mikkelsen, J. G. Gene editing by ferrying of CRISPR\/Cas ribonucleoprotein complexes in enveloped virus-derived particles. Hum. Gene Ther. 35, 604\u2013616 (2024).","journal-title":"Hum. Gene Ther."},{"key":"5270_CR157","doi-asserted-by":"crossref","unstructured":"Epstein, B. E. & Schaffer, D. V. Combining engineered nucleases with adeno-associated viral vectors for therapeutic gene editing. Precis. Med. Cris. Genome Eng. Mov. Assoc. Biol Ther. 29\u201342 (2017).","DOI":"10.1007\/978-3-319-63904-8_2"},{"key":"5270_CR158","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.2217\/fvl.13.112","volume":"8","author":"LM Drouin","year":"2013","unstructured":"Drouin, L. M. & Agbandje-McKenna, M. Adeno-associated virus structural biology as a tool in vector development. Future Virol. 8, 1183\u20131199 (2013).","journal-title":"Future Virol."},{"key":"5270_CR159","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10867-018-9488-5","volume":"44","author":"J Bernaud","year":"2018","unstructured":"Bernaud, J. et al. Characterization of AAV vector particle stability at the single-capsid level. J. Biol. Phys. 44, 181\u2013194 (2018).","journal-title":"J. Biol. Phys."},{"key":"5270_CR160","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","volume":"31","author":"MF Naso","year":"2017","unstructured":"Naso, M. F., Tomkowicz, B., Perry, W. L. III & Strohl, W. R. Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs 31, 317\u2013334 (2017).","journal-title":"BioDrugs"},{"key":"5270_CR161","doi-asserted-by":"publisher","DOI":"10.3389\/fgeed.2023.1068637","volume":"5","author":"A Shakirova","year":"2023","unstructured":"Shakirova, A., Karpov, T., Komarova, Y. & Lepik, K. In search of an ideal template for therapeutic genome editing: a review of current developments for structure optimization. Front. Genome Ed. 5, 1068637 (2023).","journal-title":"Front. Genome Ed."},{"key":"5270_CR162","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1016\/j.ymthe.2020.08.004","volume":"28","author":"NT Tran","year":"2020","unstructured":"Tran, N. T. et al. CRISPR-Cas9-mediated ELANE mutation correction in hematopoietic stem and progenitor cells to treat severe congenital neutropenia. Mol. Ther. 28, 2621\u20132634 (2020).","journal-title":"Mol. Ther."},{"key":"5270_CR163","first-page":"1777","volume":"126","author":"R Sharma","year":"2015","unstructured":"Sharma, R. et al. In vivo genome editing of the albumin locus as a platform for protein replacement therapy. Blood, J. Am. Soc. Hematol. 126, 1777\u20131784 (2015).","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"5270_CR164","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.ymthe.2018.03.002","volume":"26","author":"K Laoharawee","year":"2018","unstructured":"Laoharawee, K. et al. Dose-dependent prevention of metabolic and neurologic disease in murine MPS II by ZFN-mediated in vivo genome editing. Mol. Ther. 26, 1127\u20131136 (2018).","journal-title":"Mol. Ther."},{"key":"5270_CR165","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.omtm.2019.12.004","volume":"17","author":"DY Richards","year":"2020","unstructured":"Richards, D. Y. et al. AAV-mediated CRISPR\/Cas9 gene editing in murine phenylketonuria. Mol. Ther. Methods Clin. Dev. 17, 234\u2013245 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"5270_CR166","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07827-1","volume":"9","author":"N Zabaleta","year":"2018","unstructured":"Zabaleta, N. et al. CRISPR\/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I. Nat. Commun. 9, 5454 (2018).","journal-title":"Nat. Commun."},{"key":"5270_CR167","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s44321-023-00008-8","volume":"16","author":"L Torella","year":"2024","unstructured":"Torella, L. et al. Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1. EMBO Mol. Med. 16, 112\u2013131 (2024).","journal-title":"EMBO Mol. Med."},{"key":"5270_CR168","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41551-019-0501-5","volume":"4","author":"JM Levy","year":"2020","unstructured":"Levy, J. M. et al. Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses. Nat. Biomed. Eng. 4, 97\u2013110 (2020).","journal-title":"Nat. Biomed. Eng."},{"key":"5270_CR169","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay9101","volume":"12","author":"WH Yeh","year":"2020","unstructured":"Yeh, W. H. et al. In vivo base editing restores sensory transduction and transiently improves auditory function in a mouse model of recessive deafness. Sci. Transl. Med. 12, eaay9101 (2020).","journal-title":"Sci. Transl. Med."},{"key":"5270_CR170","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/genbio.2022.0015","volume":"1","author":"H Zhang","year":"2022","unstructured":"Zhang, H. et al. Adenine base editing in vivo with a single adeno-associated virus vector. GEN Biotechnol. 1, 285\u2013299 (2022).","journal-title":"GEN Biotechnol."},{"key":"5270_CR171","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/s41551-022-00911-4","volume":"6","author":"JR Davis","year":"2022","unstructured":"Davis, J. R. et al. Efficient in vivo base editing via single adeno-associated viruses with size-optimized genomes encoding compact adenine base editors. Nat. Biomed. Eng. 6, 1272\u20131283 (2022).","journal-title":"Nat. Biomed. Eng."},{"key":"5270_CR172","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1016\/j.ymthe.2022.07.001","volume":"30","author":"Z Gao","year":"2022","unstructured":"Gao, Z. et al. A truncated reverse transcriptase enhances prime editing by split AAV vectors. Mol. Ther. 30, 2942\u20132951 (2022).","journal-title":"Mol. Ther."},{"key":"5270_CR173","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.ymthe.2022.01.005","volume":"30","author":"C Zheng","year":"2022","unstructured":"Zheng, C. et al. A flexible split prime editor using truncated reverse transcriptase improves dual-AAV delivery in mouse liver. Mol. Ther. 30, 1343\u20131351 (2022).","journal-title":"Mol. Ther."},{"key":"5270_CR174","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.omtn.2023.08.018","volume":"33","author":"T Lan","year":"2023","unstructured":"Lan, T. et al. Mini-PE, a prime editor with compact Cas9 and truncated reverse transcriptase. Mol. Ther. Nucleic Acids 33, 890\u2013897 (2023).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"5270_CR175","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41587-023-01758-z","volume":"42","author":"JR Davis","year":"2024","unstructured":"Davis, J. R. et al. Efficient prime editing in mouse brain, liver and heart with dual AAVs. Nat. Biotechnol. 42, 253\u2013264 (2024).","journal-title":"Nat. Biotechnol."},{"key":"5270_CR176","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2025.102733","volume":"18","author":"Z Xu","year":"2025","unstructured":"Xu, Z. et al. Postpartum hemorrhage emerges as a key outcome of maternal SARS-CoV-2 omicron variant infection surge across pregnancy trimesters. J. Infect. Public Health 18, 102733 (2025).","journal-title":"J. Infect. Public Health"},{"key":"5270_CR177","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1002\/1873-3468.13691","volume":"593","author":"J Gao","year":"2019","unstructured":"Gao, J., Mese, K., Bunz, O. & Ehrhardt, A. State-of-the-art human adenovirus vectorology for therapeutic approaches. FEBS Lett. 593, 3609\u20133622 (2019).","journal-title":"FEBS Lett."},{"key":"5270_CR178","doi-asserted-by":"crossref","unstructured":"Tasca, F., Wang, Q. & Gon\u00e7alves, M. A. F. V. Adenoviral vectors meet gene editing: a rising partnership for the genomic engineering of human stem cells and their progeny. Cells. 9, 953 (2020).","DOI":"10.3390\/cells9040953"},{"key":"5270_CR179","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1089\/hum.2012.172","volume":"24","author":"DA Maier","year":"2013","unstructured":"Maier, D. A. et al. Efficient clinical scale gene modification via zinc finger nuclease\u2013targeted disruption of the HIV Co-receptor CCR5. Hum. Gene Ther. 24, 245\u2013258 (2013).","journal-title":"Hum. Gene Ther."},{"key":"5270_CR180","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1093\/nar\/gks1446","volume":"41","author":"M Holkers","year":"2013","unstructured":"Holkers, M. et al. Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells. Nucleic Acids Res. 41, e63 (2013).","journal-title":"Nucleic Acids Res."},{"key":"5270_CR181","doi-asserted-by":"publisher","DOI":"10.1038\/srep05105","volume":"4","author":"I Maggio","year":"2014","unstructured":"Maggio, I. et al. Adenoviral vector delivery of RNA-guided CRISPR\/Cas9 nuclease complexes induces targeted mutagenesis in a diverse array of human cells. Sci. Rep. 4, 5105 (2014).","journal-title":"Sci. Rep."},{"key":"5270_CR182","doi-asserted-by":"crossref","unstructured":"Ricobaraza, A. et al. High-capacity adenoviral vectors: expanding the scope of gene therapy. Int. J. Mol. Sci. 21, 3643 (2020).","DOI":"10.3390\/ijms21103643"},{"key":"5270_CR183","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.ymthe.2019.08.006","volume":"27","author":"C Li","year":"2019","unstructured":"Li, C. et al. Targeted integration and high-level transgene expression in AAVS1 transgenic mice after in vivo HSC Transduction with HDAd5\/35++ Vectors. Mol. Ther. 27, 2195\u20132212 (2019).","journal-title":"Mol. Ther."},{"key":"5270_CR184","doi-asserted-by":"publisher","first-page":"7761","DOI":"10.1093\/nar\/gkac567","volume":"50","author":"F Tasca","year":"2022","unstructured":"Tasca, F. et al. Large-scale genome editing based on high-capacity adenovectors and CRISPR-Cas9 nucleases rescues full-length dystrophin synthesis in DMD muscle cells. Nucleic Acids Res. 50, 7761\u20137782 (2022).","journal-title":"Nucleic Acids Res."},{"key":"5270_CR185","doi-asserted-by":"publisher","first-page":"11986","DOI":"10.1093\/nar\/gkab938","volume":"49","author":"Q Wang","year":"2021","unstructured":"Wang, Q. et al. Broadening the reach and investigating the potential of prime editors through fully viral gene-deleted adenoviral vector delivery. Nucleic Acids Res. 49, 11986\u201312001 (2021).","journal-title":"Nucleic Acids Res."},{"key":"5270_CR186","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1182\/bloodadvances.2020003702","volume":"5","author":"C Li","year":"2021","unstructured":"Li, C. et al. In vivo HSPC gene therapy with base editors allows for efficient reactivation of fetal \u03b3-globin in \u03b2-YAC mice. Blood Adv. 5, 1122\u20131135 (2021).","journal-title":"Blood Adv."},{"key":"5270_CR187","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41576-018-0068-0","volume":"19","author":"HA Rees","year":"2018","unstructured":"Rees, H. A. & Liu, D. R. Publisher correction: base editing: precision chemistry on the genome and transcriptome of living cells. Nat. Rev. Genet. 19, 801 (2018).","journal-title":"Nat. Rev. Genet."},{"key":"5270_CR188","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41576-022-00541-1","volume":"24","author":"PJ Chen","year":"2023","unstructured":"Chen, P. J. & Liu, D. R. Prime editing for precise and highly versatile genome manipulation. Nat. Rev. Genet. 24, 161\u2013177 (2023).","journal-title":"Nat. Rev. Genet."},{"key":"5270_CR189","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1093\/nar\/gkae057","volume":"52","author":"Q Wang","year":"2024","unstructured":"Wang, Q., Capelletti, S., Liu, J., Janssen, J. M. & Gon\u00e7alves, M. A. F. V. Selection-free precise gene repair using high-capacity adenovector delivery of advanced prime editing systems rescues dystrophin synthesis in DMD muscle cells. Nucleic Acids Res. 52, 2740\u20132757 (2024).","journal-title":"Nucleic Acids Res."},{"key":"5270_CR190","doi-asserted-by":"crossref","unstructured":"Liu, W. N. et al. Successful targeting of PD-1\/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model. Sci Adv. 8, eadd1187 (2022)","DOI":"10.1126\/sciadv.add1187"},{"key":"5270_CR191","doi-asserted-by":"crossref","unstructured":"Wang, Y. & Shao, W. Innate immune response to viral vectors in gene therapy. Viruses 15, 1801(2023).","DOI":"10.3390\/v15091801"},{"key":"5270_CR192","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1002\/1873-3468.13731","volume":"594","author":"MA Barry","year":"2020","unstructured":"Barry, M. A., Rubin, J. D. & Lu, S. Retargeting adenoviruses for therapeutic applications and vaccines. FEBS Lett. 594, 1918\u20131946 (2020).","journal-title":"FEBS Lett."},{"key":"5270_CR193","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1021\/acs.molpharmaceut.1c00916","volume":"19","author":"P Kazemian","year":"2022","unstructured":"Kazemian, P. et al. Lipid-nanoparticle-based delivery of CRISPR\/Cas9 genome-editing components. Mol. Pharm. 19, 1669\u20131686 (2022).","journal-title":"Mol. Pharm."},{"key":"5270_CR194","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115359","volume":"211","author":"R Masarwy","year":"2024","unstructured":"Masarwy, R. et al. Delivery of nucleic acid based genome editing platforms via lipid nanoparticles: Clinical applications. Adv. Drug Deliv. Rev. 211, 115359 (2024).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"5270_CR195","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams, D. et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 11\u201321 (2018).","journal-title":"N. Engl. J. Med."},{"key":"5270_CR196","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"5270_CR197","doi-asserted-by":"publisher","first-page":"614","DOI":"10.7150\/thno.47007","volume":"11","author":"S Zhang","year":"2021","unstructured":"Zhang, S., Shen, J., Li, D. & Cheng, Y. Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR\/Cas9 genome editing. Theranostics 11, 614\u2013648 (2021).","journal-title":"Theranostics"},{"key":"5270_CR198","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1021\/acs.biochem.3c00371","volume":"62","author":"J Tuma","year":"2023","unstructured":"Tuma, J. et al. Lipid nanoparticles deliver mRNA to the brain after an intracerebral injection. Biochemistry 62, 3533\u20133547 (2023).","journal-title":"Biochemistry"},{"key":"5270_CR199","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abc9450","volume":"6","author":"D Rosenblum","year":"2025","unstructured":"Rosenblum, D. et al. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Sci. Adv. 6, eabc9450 (2025).","journal-title":"Sci. Adv."},{"key":"5270_CR200","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","volume":"22","author":"JD Finn","year":"2018","unstructured":"Finn, J. D. et al. A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep. 22, 2227\u20132235 (2018).","journal-title":"Cell Rep."},{"key":"5270_CR201","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jconrel.2023.02.008","volume":"355","author":"H Onuma","year":"2023","unstructured":"Onuma, H., Sato, Y. & Harashima, H. Lipid nanoparticle-based ribonucleoprotein delivery for in vivo genome editing. J. Control Release 355, 406\u2013416 (2023).","journal-title":"J. Control Release"},{"key":"5270_CR202","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17029-3","volume":"11","author":"T Wei","year":"2020","unstructured":"Wei, T., Cheng, Q., Min, Y. L., Olson, E. N. & Siegwart, D. J. Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing. Nat. Commun. 11, 3232 (2020).","journal-title":"Nat. Commun."},{"key":"5270_CR203","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103505","volume":"28","author":"MCP Mendon\u00e7a","year":"2023","unstructured":"Mendon\u00e7a, M. C. P., Kont, A., Kowalski, P. S. & O\u2019Driscoll, C. M. Design of lipid-based nanoparticles for delivery of therapeutic nucleic acids. Drug Discov. Today 28, 103505 (2023).","journal-title":"Drug Discov. Today"},{"key":"5270_CR204","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2307796121","volume":"121","author":"CA Tsuchida","year":"2024","unstructured":"Tsuchida, C. A., Wasko, K. M., Hamilton, J. R. & Doudna, J. A. Targeted nonviral delivery of genome editors in vivo. Proc. Natl. Acad. Sci. USA 121, e2307796121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"5270_CR205","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114861","volume":"197","author":"P Khare","year":"2023","unstructured":"Khare, P., Edgecomb, S. X., Hamadani, C. M., Tanner, E. E. L. & S Manickam, D. Lipid nanoparticle-mediated drug delivery to the brain. Adv. Drug Deliv. Rev. 197, 114861 (2023).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"5270_CR206","doi-asserted-by":"publisher","first-page":"7413","DOI":"10.1073\/pnas.84.21.7413","volume":"84","author":"PL Felgner","year":"1987","unstructured":"Felgner, P. L. et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. USA 84, 7413\u20137417 (1987).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"5270_CR207","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37465-1","volume":"14","author":"LN Kasiewicz","year":"2023","unstructured":"Kasiewicz, L. N. et al. GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy. Nat. Commun. 14, 2776 (2023).","journal-title":"Nat. Commun."},{"key":"5270_CR208","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","volume":"593","author":"K Musunuru","year":"2021","unstructured":"Musunuru, K. et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 593, 429\u2013434 (2021).","journal-title":"Nature"},{"key":"5270_CR209","doi-asserted-by":"publisher","first-page":"10464","DOI":"10.1021\/acsami.2c21683","volume":"15","author":"M Zhu","year":"2023","unstructured":"Zhu, M. et al. Guanidinium-rich lipopeptide-based nanoparticle enables efficient gene editing in skeletal muscles. ACS Appl. Mater. Interfaces 15, 10464\u201310476 (2023).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"5270_CR210","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jconrel.2022.08.042","volume":"350","author":"SZ Mirjalili Mohanna","year":"2022","unstructured":"Mirjalili Mohanna, S. Z. et al. LNP-mediated delivery of CRISPR RNP for wide-spread in vivo genome editing in mouse cornea. J. Control Release 350, 401\u2013413 (2022).","journal-title":"J. Control Release"},{"key":"5270_CR211","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42948-2","volume":"14","author":"T Wei","year":"2023","unstructured":"Wei, T. et al. Lung SORT LNPs enable precise homology-directed repair mediated CRISPR\/Cas genome correction in cystic fibrosis models. Nat. Commun. 14, 7322 (2023).","journal-title":"Nat. Commun."},{"key":"5270_CR212","doi-asserted-by":"crossref","unstructured":"Farbiak, L. et al. All-in-one dendrimer-based lipid nanoparticles enable precise HDR-mediated gene editing in vivo. Adv Mater. 33, 2006619 (2021).","DOI":"10.1002\/adma.202006619"},{"key":"5270_CR213","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1208\/s12248-023-00833-2","volume":"25","author":"M Herrera-Barrera","year":"2023","unstructured":"Herrera-Barrera, M. et al. Lipid nanoparticle-enabled intracellular delivery of prime editors. AAPS J. 25, 65 (2023).","journal-title":"AAPS J."},{"key":"5270_CR214","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41573-024-00977-6","volume":"23","author":"PR Cullis","year":"2024","unstructured":"Cullis, P. R. & Felgner, P. L. The 60-year evolution of lipid nanoparticles for nucleic acid delivery. Nat. Rev. Drug Discov. 23, 709\u2013722 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"5270_CR215","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1182\/blood.2022019333","volume":"142","author":"V Vavassori","year":"2023","unstructured":"Vavassori, V. et al. Lipid nanoparticles allow efficient and harmless ex vivo gene editing of human hematopoietic cells. Blood 142, 812\u2013826 (2023).","journal-title":"Blood"},{"key":"5270_CR216","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing. Nat. Nanotechnol. 15, 313\u2013320 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"5270_CR217","doi-asserted-by":"crossref","unstructured":"Marques, A. C., Costa, P. C., Velho, S. & Amaral, M. H. Lipid nanoparticles functionalized with antibodies for anticancer drug therapy. Pharmaceutics 15, 216 (2023).","DOI":"10.3390\/pharmaceutics15010216"},{"key":"5270_CR218","doi-asserted-by":"crossref","unstructured":"Kularatne, R. N., Crist, R. M. & Stern, S. T. The future of tissue-targeted lipid nanoparticle-mediated nucleic acid delivery. Pharmaceuticals 15, 897 (2022).","DOI":"10.3390\/ph15070897"},{"key":"5270_CR219","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1038\/s41591-023-02699-5","volume":"29","author":"C Arnold","year":"2023","unstructured":"Arnold, C. & Webster, P. 11 clinical trials that will shape medicine in 2024. Nat. Med. 29, 2964\u20132968 (2023).","journal-title":"Nat. Med."},{"key":"5270_CR220","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2020401118","volume":"118","author":"M Qiu","year":"2021","unstructured":"Qiu, M. et al. Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3. Proc. Natl. Acad. Sci. USA 118, e2020401118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"5270_CR221","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore, J. D. et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N. Engl. J. Med. 385, 493\u2013502 (2021).","journal-title":"N. Engl. J. Med."},{"key":"5270_CR222","doi-asserted-by":"crossref","unstructured":"Buschmann, M. D. et al. Nanomaterial delivery systems for mRNA Vaccines. Vaccines 9, 65 (2021).","DOI":"10.3390\/vaccines9010065"},{"key":"5270_CR223","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26714-w","volume":"12","author":"E Kenjo","year":"2021","unstructured":"Kenjo, E. et al. Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice. Nat. Commun. 12, 7101 (2021).","journal-title":"Nat. Commun."},{"key":"5270_CR224","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41596-022-00755-x","volume":"18","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery. Nat. Protoc. 18, 265\u2013291 (2023).","journal-title":"Nat. Protoc."},{"key":"5270_CR225","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.123990","volume":"654","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y., Gu, X., Huang, L., Yang, Y. & He, J. Enhancing precision medicine: Bispecific antibody-mediated targeted delivery of lipid nanoparticles for potential cancer therapy. Int. J. Pharm. 654, 123990 (2024).","journal-title":"Int. J. Pharm."},{"key":"5270_CR226","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.molmed.2023.02.004","volume":"29","author":"WM Pardridge","year":"2023","unstructured":"Pardridge, W. M. Brain gene therapy with Trojan horse lipid nanoparticles. Trends Mol. Med. 29, 343\u2013353 (2023).","journal-title":"Trends Mol. Med."},{"key":"5270_CR227","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.imlet.2019.07.008","volume":"213","author":"E Chen","year":"2019","unstructured":"Chen, E., Chen, C., Chen, F., Yu, P. & Lin, L. Positive association between MIC gene polymorphism and tuberculosis in Chinese population. Immunol. Lett. 213, 62\u201369 (2019).","journal-title":"Immunol. Lett."},{"key":"5270_CR228","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.ymthe.2023.02.013","volume":"31","author":"J R\u00e4dler","year":"2023","unstructured":"R\u00e4dler, J., Gupta, D., Zickler, A. & Andaloussi, S. E. L. Exploiting the biogenesis of extracellular vesicles for bioengineering and therapeutic cargo loading. Mol. Ther. 31, 1231\u20131250 (2023).","journal-title":"Mol. Ther."},{"key":"5270_CR229","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau6977","volume":"367","author":"R Kalluri","year":"2020","unstructured":"Kalluri, R. & LeBleu, V. S. The biology, function, and biomedical applications of exosomes. Science 367, eaau6977 (2020).","journal-title":"Science"},{"key":"5270_CR230","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.113961","volume":"178","author":"D Gupta","year":"2021","unstructured":"Gupta, D., Zickler, A. M. & El Andaloussi, S. Dosing extracellular vesicles. Adv. Drug Deliv. Rev. 178, 113961 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"5270_CR231","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.1109\/TCBB.2022.3143770","volume":"19","author":"W Li","year":"2022","unstructured":"Li, W., Wang, S., Xu, J. & Xiang, J. Inferring Latent MicroRNA-disease associations on a gene-mediated tripartite heterogeneous multiplexing network. IEEE\/ACM Trans. Comput. Biol. Bioinform. 19, 3190\u20133201 (2022).","journal-title":"IEEE\/ACM Trans. Comput. Biol. Bioinform."},{"key":"5270_CR232","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jconrel.2023.12.050","volume":"366","author":"X Pan","year":"2024","unstructured":"Pan, X., Li, Y., Huang, P., Staecker, H. & He, M. Extracellular vesicles for developing targeted hearing loss therapy. J. Control Release 366, 460\u2013478 (2024).","journal-title":"J. Control Release"},{"key":"5270_CR233","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jconrel.2017.09.013","volume":"266","author":"SM Kim","year":"2017","unstructured":"Kim, S. M. et al. Cancer-derived exosomes as a delivery platform of CRISPR\/Cas9 confer cancer cell tropism-dependent targeting. J. Control Release 266, 8\u201316 (2017).","journal-title":"J. Control Release"},{"key":"5270_CR234","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1016\/j.ymthe.2022.05.023","volume":"30","author":"N Majeau","year":"2022","unstructured":"Majeau, N. et al. Serum extracellular vesicles for delivery of CRISPR-CAS9 ribonucleoproteins to modify the dystrophin gene. Mol. Ther. 30, 2429\u20132442 (2022).","journal-title":"Mol. Ther."},{"key":"5270_CR235","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14957-y","volume":"11","author":"P Gee","year":"2020","unstructured":"Gee, P. et al. Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping. Nat. Commun. 11, 1334 (2020).","journal-title":"Nat. Commun."},{"key":"5270_CR236","doi-asserted-by":"crossref","unstructured":"Borchers, A. & Pieler, T. Programming pluripotent precursor cells derived from xenopus embryos to generate specific tissues and organs. Genes 1, 413\u2013426 (2010).","DOI":"10.3390\/genes1030413"},{"key":"5270_CR237","doi-asserted-by":"publisher","DOI":"10.1590\/1806-9282.20230188","volume":"70","author":"S Nouri","year":"2024","unstructured":"Nouri, S. et al. NAMPT gene rs2058539 variant is a risk factor for nonalcoholic fatty liver disease. Rev. Assoc. Med. Bras. 70, e20230188 (2024).","journal-title":"Rev. Assoc. Med. Bras."},{"key":"5270_CR238","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41596-020-00431-y","volume":"16","author":"XR Bao","year":"2021","unstructured":"Bao, X. R., Pan, Y., Lee, C. M., Davis, T. H. & Bao, G. Tools for experimental and computational analyses of off-target editing by programmable nucleases. Nat. Protoc. 16, 10\u201326 (2021).","journal-title":"Nat. Protoc."},{"key":"5270_CR239","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/bioinformatics\/btt764","volume":"30","author":"A Xiao","year":"2014","unstructured":"Xiao, A. et al. CasOT: a genome-wide Cas9\/gRNA off-target searching tool. Bioinformatics 30, 1180\u20131182 (2014).","journal-title":"Bioinformatics"},{"key":"5270_CR240","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1093\/bioinformatics\/btu048","volume":"30","author":"S Bae","year":"2014","unstructured":"Bae, S., Park, J. & Kim, J. S. Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics 30, 1473\u20131475 (2014).","journal-title":"Bioinformatics"},{"key":"5270_CR241","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-018-0545-0","volume":"16","author":"A McKenna","year":"2018","unstructured":"McKenna, A. & Shendure, J. FlashFry: a fast and flexible tool for large-scale CRISPR target design. BMC Biol. 16, 74 (2018).","journal-title":"BMC Biol."},{"key":"5270_CR242","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1093\/bioinformatics\/btz019","volume":"35","author":"ALS Jacquin","year":"2019","unstructured":"Jacquin, A. L. S., Odom, D. T. & Lukk, M. Crisflash: open-source software to generate CRISPR guide RNAs against genomes annotated with individual variation. Bioinformatics 35, 3146\u20133147 (2019).","journal-title":"Bioinformatics"},{"key":"5270_CR243","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1012-2","volume":"17","author":"M Haeussler","year":"2016","unstructured":"Haeussler, M. et al. Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR. Genome Biol. 17, 148 (2016).","journal-title":"Genome Biol."},{"key":"5270_CR244","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/nbt.2647","volume":"31","author":"PD Hsu","year":"2013","unstructured":"Hsu, P. D. et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 31, 827\u2013832 (2013).","journal-title":"Nat. Biotechnol."},{"key":"5270_CR245","doi-asserted-by":"publisher","first-page":"e0124633","DOI":"10.1371\/journal.pone.0124633","volume":"10","author":"M Stemmer","year":"2015","unstructured":"Stemmer, M. et al. CCTop: an intuitive, flexible and reliable CRISPR\/Cas9 Target Prediction Tool. PLoS ONE 10, e0124633 (2015).","journal-title":"PLoS ONE"},{"key":"5270_CR246","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1093\/nar\/gkv575","volume":"43","author":"R Singh","year":"2015","unstructured":"Singh, R., Kuscu, C., Quinlan, A., Qi, Y. & Adli, M. Cas9-chromatin binding information enables more accurate CRISPR off-target prediction. Nucleic Acids Res. 43, e118 (2015).","journal-title":"Nucleic Acids Res."},{"key":"5270_CR247","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184\u2013191 (2016).","journal-title":"Nat. Biotechnol."},{"key":"5270_CR248","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-018-1459-4","volume":"19","author":"G Chuai","year":"2018","unstructured":"Chuai, G. et al. DeepCRISPR: optimized CRISPR guide RNA design by deep learning. Genome Biol. 19, 80 (2018).","journal-title":"Genome Biol."},{"key":"5270_CR249","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41551-017-0178-6","volume":"2","author":"J Listgarten","year":"2018","unstructured":"Listgarten, J. et al. Prediction of off-target activities for the end-to-end design of CRISPR guide RNAs. Nat. Biomed. Eng. 2, 38\u201347 (2018).","journal-title":"Nat. Biomed. Eng."},{"key":"5270_CR250","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nature24268","volume":"550","author":"JS Chen","year":"2017","unstructured":"Chen, J. S. et al. Enhanced proofreading governs CRISPR-Cas9 targeting accuracy. Nature 550, 407\u2013410 (2017).","journal-title":"Nature"},{"key":"5270_CR251","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nature16526","volume":"529","author":"BP Kleinstiver","year":"2016","unstructured":"Kleinstiver, B. P. et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature 529, 490\u2013495 (2016).","journal-title":"Nature"},{"key":"5270_CR252","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.aad5227","volume":"351","author":"IM Slaymaker","year":"2016","unstructured":"Slaymaker, I. M. et al. Rationally engineered Cas9 nucleases with improved specificity. Science 351, 84\u201388 (2016).","journal-title":"Science"},{"key":"5270_CR253","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nbt.4066","volume":"36","author":"A Casini","year":"2018","unstructured":"Casini, A. et al. A highly specific SpCas9 variant is identified by in vivo screening in yeast. Nat. Biotechnol. 36, 265\u2013271 (2018).","journal-title":"Nat. Biotechnol."},{"key":"5270_CR254","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature14592","volume":"523","author":"BP Kleinstiver","year":"2015","unstructured":"Kleinstiver, B. P. et al. Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature 523, 481\u2013485 (2015).","journal-title":"Nature"},{"key":"5270_CR255","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nbt.3101","volume":"33","author":"RL Frock","year":"2015","unstructured":"Frock, R. L. et al. Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. Nat. Biotechnol. 33, 179\u2013186 (2015).","journal-title":"Nat. Biotechnol."},{"key":"5270_CR256","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3389\/fnmol.2018.00413","volume":"11","author":"N Kumar","year":"2018","unstructured":"Kumar, N. et al. The Development of an AAV-Based CRISPR SaCas9 genome editing system that can be delivered to neurons in vivo and regulated via doxycycline and Cre-Recombinase. Front. Mol. Neurosci. 11, 413 (2018).","journal-title":"Front. Mol. Neurosci."},{"key":"5270_CR257","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/mt.2015.218","volume":"24","author":"M M\u00fcller","year":"2016","unstructured":"M\u00fcller, M. et al. Streptococcus thermophilus CRISPR-Cas9 systems enable specific editing of the human genome. Mol. Ther. 24, 636\u2013644 (2016).","journal-title":"Mol. Ther."},{"key":"5270_CR258","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1101\/gr.162339.113","volume":"24","author":"SW Cho","year":"2014","unstructured":"Cho, S. W. et al. Analysis of off-target effects of CRISPR\/Cas-derived RNA-guided endonucleases and nickases. Genome Res. 24, 132\u2013141 (2014).","journal-title":"Genome Res."},{"key":"5270_CR259","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nbt.2808","volume":"32","author":"Y Fu","year":"2014","unstructured":"Fu, Y., Sander, J. D., Reyon, D., Cascio, V. M. & Joung, J. K. Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat. Biotechnol. 32, 279\u2013284 (2014).","journal-title":"Nat. Biotechnol."},{"key":"5270_CR260","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1101\/gr.199588.115","volume":"26","author":"D Kim","year":"2016","unstructured":"Kim, D., Kim, S., Kim, S., Park, J. & Kim, J. S. Genome-wide target specificities of CRISPR-Cas9 nucleases revealed by multiplex Digenome-seq. Genome Res. 26, 406\u2013415 (2016).","journal-title":"Genome Res."},{"key":"5270_CR261","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nbt.3852","volume":"35","author":"D Kim","year":"2017","unstructured":"Kim, D. et al. Genome-wide target specificities of CRISPR RNA-guided programmable deaminases. Nat. Biotechnol. 35, 475\u2013480 (2017).","journal-title":"Nat. Biotechnol."},{"key":"5270_CR262","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07988-z","volume":"10","author":"P Liang","year":"2019","unstructured":"Liang, P. et al. Genome-wide profiling of adenine base editor specificity by EndoV-seq. Nat. Commun. 10, 67 (2019).","journal-title":"Nat. Commun."},{"key":"5270_CR263","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev-biochem-013118-111730","volume":"88","author":"D Kim","year":"2019","unstructured":"Kim, D., Luk, K., Wolfe, S. A. & Kim, J. S. Evaluating and enhancing target specificity of gene-editing nucleases and deaminases. Annu. Rev. Biochem. 88, 191\u2013220 (2019).","journal-title":"Annu. Rev. Biochem."},{"key":"5270_CR264","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1093\/nar\/gkx1199","volume":"46","author":"DE Ryan","year":"2018","unstructured":"Ryan, D. E. et al. Improving CRISPR-Cas specificity with chemical modifications in single-guide RNAs. Nucleic Acids Res. 46, 792\u2013803 (2018).","journal-title":"Nucleic Acids Res."},{"key":"5270_CR265","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03927-0","volume":"9","author":"CR Cromwell","year":"2018","unstructured":"Cromwell, C. R. et al. Incorporation of bridged nucleic acids into CRISPR RNAs improves Cas9 endonuclease specificity. Nat. Commun. 9, 1448 (2018).","journal-title":"Nat. Commun."},{"key":"5270_CR266","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/nchembio.2559","volume":"14","author":"H Yin","year":"2018","unstructured":"Yin, H. et al. Partial DNA-guided Cas9 enables genome editing with reduced off-target activity. Nat. Chem. Biol. 14, 311\u2013316 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"5270_CR267","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1111\/pbi.13838","volume":"20","author":"Y Wu","year":"2022","unstructured":"Wu, Y. et al. Genome-wide analyses of PAM-relaxed Cas9 genome editors reveal substantial off-target effects by ABE8e in rice. Plant Biotechnol. J. 20, 1670\u20131682 (2022).","journal-title":"Plant Biotechnol. J."},{"key":"5270_CR268","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41586-019-1161-z","volume":"569","author":"J Gr\u00fcnewald","year":"2019","unstructured":"Gr\u00fcnewald, J. et al. Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors. Nature 569, 433\u2013437 (2019).","journal-title":"Nature"},{"key":"5270_CR269","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1126\/science.aaw7166","volume":"364","author":"S Jin","year":"2019","unstructured":"Jin, S. et al. Cytosine, but not adenine, base editors induce genome-wide off-target mutations in rice. Science 364, 292\u2013295 (2019).","journal-title":"Science"},{"key":"5270_CR270","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41586-019-1314-0","volume":"571","author":"C Zhou","year":"2019","unstructured":"Zhou, C. et al. Off-target RNA mutation induced by DNA base editing and its elimination by mutagenesis. Nature 571, 275\u2013278 (2019).","journal-title":"Nature"},{"key":"5270_CR271","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1126\/science.aav9973","volume":"364","author":"E Zuo","year":"2019","unstructured":"Zuo, E. et al. Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos. Science 364, 289\u2013292 (2019).","journal-title":"Science"},{"key":"5270_CR272","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/s41587-020-0453-z","volume":"38","author":"MF Richter","year":"2020","unstructured":"Richter, M. F. et al. Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity. Nat. Biotechnol. 38, 883\u2013891 (2020).","journal-title":"Nat. Biotechnol."},{"key":"5270_CR273","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.molcel.2020.07.005","volume":"79","author":"S Jin","year":"2020","unstructured":"Jin, S. et al. Rationally designed APOBEC3B cytosine base editors with improved specificity. Mol. Cell 79, 728\u2013740.e6 (2020).","journal-title":"Mol. Cell"},{"key":"5270_CR274","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s41592-021-01172-w","volume":"18","author":"Z Lei","year":"2021","unstructured":"Lei, Z. et al. Detect-seq reveals out-of-protospacer editing and target-strand editing by cytosine base editors. Nat. Methods 18, 643\u2013651 (2021).","journal-title":"Nat. Methods"},{"key":"5270_CR275","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/nm0817-900","volume":"23","author":"C Willyard","year":"2017","unstructured":"Willyard, C. The epigenome editors: how tools such as CRISPR offer new details about epigenetics. Nat. Med. 23, 900\u2013903 (2017).","journal-title":"Nat. Med."},{"key":"5270_CR276","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jconrel.2022.01.013","volume":"342","author":"EA Taha","year":"2022","unstructured":"Taha, E. A., Lee, J. & Hotta, A. Delivery of CRISPR-Cas tools for in vivo genome editing therapy: trends and challenges. J. Control Release Soc. 342, 345\u2013361 (2022).","journal-title":"J. Control Release Soc."},{"key":"5270_CR277","first-page":"153","volume":"17","author":"A Lohia","year":"2022","unstructured":"Lohia, A. et al. Delivery strategies for CRISPR\/Cas genome editing tool for retinal dystrophies: challenges and opportunities. Asian J. Pharm. Sci. 17, 153\u2013176 (2022).","journal-title":"Asian J. Pharm. Sci."},{"key":"5270_CR278","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1101\/gr.171264.113","volume":"24","author":"S Ramakrishna","year":"2014","unstructured":"Ramakrishna, S. et al. Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Genome Res. 24, 1020\u20131027 (2014).","journal-title":"Genome Res."},{"key":"5270_CR279","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1101\/gr.171322.113","volume":"24","author":"S Kim","year":"2014","unstructured":"Kim, S., Kim, D., Cho, S. W., Kim, J. & Kim, J. S. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 24, 1012\u20131019 (2014).","journal-title":"Genome Res."},{"key":"5270_CR280","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202202127","volume":"12","author":"X Yu","year":"2023","unstructured":"Yu, X. et al. Lipid nanoparticle delivery of chemically modified NGF(R100W) mRNA alleviates peripheral neuropathy. Adv. Health. Mater. 12, e2202127 (2023).","journal-title":"Adv. Health. Mater."},{"key":"5270_CR281","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jconrel.2022.01.027","volume":"343","author":"MJW Evers","year":"2022","unstructured":"Evers, M. J. W. et al. Delivery of modified mRNA to damaged myocardium by systemic administration of lipid nanoparticles. J. Control Release Soc. 343, 207\u2013216 (2022).","journal-title":"J. Control Release Soc."},{"key":"5270_CR282","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3389\/fbioe.2020.00547","volume":"8","author":"L Zhu","year":"2020","unstructured":"Zhu, L. et al. NAIGO: an improved method to align PPI networks based on gene ontology and graphlets. Front. Bioeng. Biotechnol. 8, 547 (2020).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"5270_CR283","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1093\/nar\/gkz093","volume":"47","author":"B Lu","year":"2019","unstructured":"Lu, B. et al. Delivering SaCas9 mRNA by lentivirus-like bionanoparticles for transient expression and efficient genome editing. Nucleic Acids Res. 47, e44 (2019).","journal-title":"Nucleic Acids Res."},{"key":"5270_CR284","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12449-2","volume":"10","author":"KS Hanlon","year":"2019","unstructured":"Hanlon, K. S. et al. High levels of AAV vector integration into CRISPR-induced DNA breaks. Nat. Commun. 10, 4439 (2019).","journal-title":"Nat. Commun."},{"key":"5270_CR285","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1073\/pnas.1520244113","volume":"113","author":"M Wang","year":"2016","unstructured":"Wang, M. et al. Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles. Proc. Natl. Acad. Sci. USA 113, 2868\u20132873 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"5270_CR286","first-page":"641","volume":"17","author":"H Ju","year":"2022","unstructured":"Ju, H., Kim, D. & Oh, Y. K. Lipid nanoparticle-mediated CRISPR\/Cas9 gene editing and metabolic engineering for anticancer immunotherapy. Asian J. Pharm. Sci. 17, 641\u2013652 (2022).","journal-title":"Asian J. Pharm. Sci."},{"key":"5270_CR287","doi-asserted-by":"publisher","first-page":"5251","DOI":"10.1039\/D2TB02610D","volume":"11","author":"MW Ghani","year":"2023","unstructured":"Ghani, M. W. et al. Recent advances in nanocomposite-based delivery systems for targeted CRISPR\/Cas delivery and therapeutic genetic manipulation. J. Mater. Chem. B 11, 5251\u20135271 (2023).","journal-title":"J. Mater. Chem. B"},{"key":"5270_CR288","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nbt.3081","volume":"33","author":"JA Zuris","year":"2015","unstructured":"Zuris, J. A. et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat. Biotechnol. 33, 73\u201380 (2015).","journal-title":"Nat. Biotechnol."},{"key":"5270_CR289","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.ymthe.2020.03.015","volume":"28","author":"L Teboul","year":"2020","unstructured":"Teboul, L., Herault, Y., Wells, S., Qasim, W. & Pavlovic, G. Variability in genome editing outcomes: challenges for research reproducibility and clinical safety. Mol. Ther. 28, 1422\u20131431 (2020).","journal-title":"Mol. Ther."},{"key":"5270_CR290","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1007\/s00216-024-05301-0","volume":"416","author":"J Luo","year":"2024","unstructured":"Luo, J. et al. A Dual-mode platform for the rapid detection of Escherichia coli O157:H7 based on CRISPR\/Cas12a and RPA. Anal. Bioanal. Chem. 416, 3509\u20133518 (2024).","journal-title":"Anal. Bioanal. Chem."},{"key":"5270_CR291","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nbt.3127","volume":"33","author":"X Wang","year":"2015","unstructured":"Wang, X. et al. Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. Nat. Biotechnol. 33, 175\u2013178 (2015).","journal-title":"Nat. Biotechnol."},{"key":"5270_CR292","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nbt.2623","volume":"31","author":"Y Fu","year":"2013","unstructured":"Fu, Y. et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol. 31, 822\u2013826 (2013).","journal-title":"Nat. Biotechnol."},{"key":"5270_CR293","doi-asserted-by":"publisher","first-page":"e1007503","DOI":"10.1371\/journal.pgen.1007503","volume":"14","author":"V Iyer","year":"2018","unstructured":"Iyer, V. et al. No unexpected CRISPR-Cas9 off-target activity revealed by trio sequencing of gene-edited mice. PLoS Genet. 14, e1007503 (2018).","journal-title":"PLoS Genet."},{"key":"5270_CR294","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nbt.3117","volume":"33","author":"SQ Tsai","year":"2015","unstructured":"Tsai, S. Q. et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat. Biotechnol. 33, 187\u2013197 (2015).","journal-title":"Nat. Biotechnol."},{"key":"5270_CR295","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.cell.2013.08.021","volume":"154","author":"FA Ran","year":"2013","unstructured":"Ran, F. A. et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154, 1380\u20131389 (2013).","journal-title":"Cell"},{"key":"5270_CR296","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nbt.2908","volume":"32","author":"SQ Tsai","year":"2014","unstructured":"Tsai, S. Q. et al. Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat. Biotechnol. 32, 569\u2013576 (2014).","journal-title":"Nat. Biotechnol."},{"key":"5270_CR297","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00109-020-01893-z","volume":"98","author":"HA Han","year":"2020","unstructured":"Han, H. A., Pang, J. K. S. & Soh, B. S. Mitigating off-target effects in CRISPR\/Cas9-mediated in vivo gene editing. J. Mol. Med. 98, 615\u2013632 (2020).","journal-title":"J. Mol. Med."},{"key":"5270_CR298","doi-asserted-by":"crossref","unstructured":"Aram, C., Firuzpour, F., Barancheshmeh, M. & Kamali, M. J. Unveiling the translational and therapeutic potential of small interfering RNA molecules in combating SARS-CoV-2: a review. Int. J. Biol. Macromol. 318, 145203 (2025).","DOI":"10.1016\/j.ijbiomac.2025.145203"},{"key":"5270_CR299","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.celrep.2015.01.016","volume":"10","author":"K Kraft","year":"2015","unstructured":"Kraft, K. et al. Deletions, inversions, duplications: engineering of structural variants using CRISPR\/Cas in Mice. Cell Rep. 10, 833\u2013839 (2015).","journal-title":"Cell Rep."},{"key":"5270_CR300","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s42003-019-0321-x","volume":"2","author":"DR Simeonov","year":"2019","unstructured":"Simeonov, D. R. et al. A large CRISPR-induced bystander mutation causes immune dysregulation. Commun. Biol. 2, 70 (2019).","journal-title":"Commun. Biol."},{"key":"5270_CR301","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nbt.3190","volume":"33","author":"T Maruyama","year":"2015","unstructured":"Maruyama, T. et al. Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nat. Biotechnol. 33, 538\u2013542 (2015).","journal-title":"Nat. Biotechnol."},{"key":"5270_CR302","doi-asserted-by":"publisher","first-page":"4289","DOI":"10.1111\/febs.13416","volume":"282","author":"SV Vartak","year":"2015","unstructured":"Vartak, S. V. & Raghavan, S. C. Inhibition of nonhomologous end joining to increase the specificity of CRISPR\/Cas9 genome editing. FEBS J. 282, 4289\u20134294 (2015).","journal-title":"FEBS J."},{"key":"5270_CR303","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.38","volume":"3","author":"SR Lin","year":"2014","unstructured":"Lin, S. R. et al. The CRISPR\/Cas9 system facilitates clearance of the intrahepatic HBV Templates in vivo. Mol. Ther. Nucleic Acids 3, e186 (2014).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"5270_CR304","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nbt.3198","volume":"33","author":"VT Chu","year":"2015","unstructured":"Chu, V. T. et al. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nat. Biotechnol. 33, 543\u2013548 (2015).","journal-title":"Nat. Biotechnol."},{"key":"5270_CR305","doi-asserted-by":"crossref","unstructured":"Seelos, H. J. A new paradigm of medical informatics. Methods Inform. Med. 31, 79\u201381 (1992).","DOI":"10.1055\/s-0038-1634861"},{"key":"5270_CR306","doi-asserted-by":"crossref","unstructured":"Xu, C. L., Ruan, M. Z. C., Mahajan, V. B. & Tsang, S. H. Viral delivery systems for CRISPR. Viruses 11, 28 (2019)","DOI":"10.3390\/v11010028"},{"key":"5270_CR307","first-page":"197","volume":"1866","author":"L Yi","year":"2016","unstructured":"Yi, L. & Li, J. CRISPR-Cas9 therapeutics in cancer: promising strategies and present challenges. Biochim. Biophys. Acta 1866, 197\u2013207 (2016).","journal-title":"Biochim. Biophys. Acta"},{"key":"5270_CR308","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.12688\/f1000research.11243.1","volume":"6","author":"CH Lau","year":"2017","unstructured":"Lau, C. H. & Suh, Y. In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease. F1000Research 6, 2153 (2017).","journal-title":"F1000Research"},{"key":"5270_CR309","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1101\/gr.231936.117","volume":"28","author":"S Kim","year":"2018","unstructured":"Kim, S. et al. CRISPR RNAs trigger innate immune responses in human cells. Genome Res. 28, 367\u2013373 (2018).","journal-title":"Genome Res."},{"key":"5270_CR310","doi-asserted-by":"crossref","unstructured":"Berardo, C. et al. Comparison between Lipofectamine RNAiMAX and GenMute transfection agents in two cellular models of human hepatoma. Eur. J. Histochem. 63, 3048 (2019).","DOI":"10.4081\/ejh.2019.3048"},{"key":"5270_CR311","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s10529-016-2064-9","volume":"38","author":"X Yu","year":"2016","unstructured":"Yu, X. et al. Improved delivery of Cas9 protein\/gRNA complexes using lipofectamine CRISPRMAX. Biotechnol. Lett. 38, 919\u2013929 (2016).","journal-title":"Biotechnol. Lett."},{"key":"5270_CR312","doi-asserted-by":"publisher","first-page":"11965","DOI":"10.1128\/JVI.01879-14","volume":"88","author":"EM Kennedy","year":"2014","unstructured":"Kennedy, E. M. et al. Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR\/Cas RNA-guided endonuclease. J. Virol. 88, 11965\u201311972 (2014).","journal-title":"J. Virol."},{"key":"5270_CR313","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1166\/jbn.2018.2604","volume":"14","author":"W Jin","year":"2018","unstructured":"Jin, W. et al. Transfection of difficult-to-transfect rat primary cortical neurons with magnetic nanoparticles. J. Biomed. Nanotechnol. 14, 1654\u20131664 (2018).","journal-title":"J. Biomed. Nanotechnol."},{"key":"5270_CR314","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/978-1-4939-6518-2_7","volume":"1507","author":"B Suresh","year":"2017","unstructured":"Suresh, B., Ramakrishna, S. & Kim, H. Cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA for genome editing. Methods Mol. Biol. 1507, 81\u201394 (2017).","journal-title":"Methods Mol. Biol."},{"key":"5270_CR315","doi-asserted-by":"publisher","first-page":"12029","DOI":"10.1002\/anie.201506030","volume":"54","author":"W Sun","year":"2015","unstructured":"Sun, W. et al. Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing. Angew. Chem. Int. Ed. Engl. 54, 12029\u201312033 (2015).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"5270_CR316","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1002\/anie.201708689","volume":"57","author":"P Wang","year":"2018","unstructured":"Wang, P. et al. Thermo-triggered Release of CRISPR-Cas9 system by lipid-encapsulated gold nanoparticles for tumor therapy. Angew. Chem. Int. Ed. Engl. 57, 1491\u20131496 (2018).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"5270_CR317","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jconrel.2004.04.024","volume":"98","author":"K Kogure","year":"2004","unstructured":"Kogure, K. et al. Development of a non-viral multifunctional envelope-type nano device by a novel lipid film hydration method. J. Control Release 98, 317\u2013323 (2004).","journal-title":"J. Control Release"},{"key":"5270_CR318","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1021\/ar200254s","volume":"45","author":"T Nakamura","year":"2012","unstructured":"Nakamura, T., Akita, H., Yamada, Y., Hatakeyama, H. & Harashima, H. A multifunctional envelope-type nanodevice for use in nanomedicine: concept and applications. Acc. Chem. Res. 45, 1113\u20131121 (2012).","journal-title":"Acc. Chem. Res."},{"key":"5270_CR319","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","volume":"25","author":"CA Lino","year":"2018","unstructured":"Lino, C. A., Harper, J. C., Carney, J. P. & Timlin, J. A. Delivering CRISPR: a review of the challenges and approaches. Drug Deliv. 25, 1234\u20131257 (2018).","journal-title":"Drug Deliv."},{"key":"5270_CR320","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1335901","volume":"11","author":"S Dixit","year":"2023","unstructured":"Dixit, S., Kumar, A., Srinivasan, K., Vincent, P. M. D. R. & Ramu Krishnan, N. Advancing genome editing with artificial intelligence: opportunities, challenges, and future directions. Front. Bioeng. Biotechnol. 11, 1335901 (2023).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"5270_CR321","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41746-025-01471-y","volume":"8","author":"E Fountzilas","year":"2025","unstructured":"Fountzilas, E., Pearce, T., Baysal, M. A., Chakraborty, A. & Tsimberidou, A. M. Convergence of evolving artificial intelligence and machine learning techniques in precision oncology. NPJ Digit Med. 8, 75 (2025).","journal-title":"NPJ Digit Med."},{"key":"5270_CR322","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1007\/s10528-024-10799-1","volume":"63","author":"M Danaeifar","year":"2025","unstructured":"Danaeifar, M. & Najafi, A. Artificial intelligence and computational biology in gene therapy: a review. Biochem. Genet. 63, 960\u2013983 (2025).","journal-title":"Biochem. Genet."},{"key":"5270_CR323","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6782046","volume":"2020","author":"B He","year":"2020","unstructured":"He, B. et al. Gene coexpression network and module analysis across 52 human tissues. Biomed. Res. Int. 2020, 6782046 (2020).","journal-title":"Biomed. Res. Int."},{"key":"5270_CR324","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-0716-4690-8_14","volume":"2952","author":"S Khammampalli","year":"2025","unstructured":"Khammampalli, S. & Vindal, V. Artificial intelligence in CRISPR-Cas Systems: a review of tool applications. Methods Mol. Biol. 2952, 243\u2013257 (2025).","journal-title":"Methods Mol. Biol."},{"key":"5270_CR325","doi-asserted-by":"crossref","unstructured":"He, B. et al. DGHNE: network enhancement-based method in identifying disease-causing genes through a heterogeneous biomedical network. Brief Bioinform. 23, bbac405 (2022).","DOI":"10.1093\/bib\/bbac405"},{"key":"5270_CR326","doi-asserted-by":"crossref","unstructured":"Xiang, J., Zhang, J., Zheng, R., Li, X. & Li, M. NIDM: network impulsive dynamics on multiplex biological network for disease-gene prediction. Brief Bioinform. 22, bbab080 (2021).","DOI":"10.1093\/bib\/bbab080"},{"key":"5270_CR327","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101208","volume":"32","author":"M Pille","year":"2024","unstructured":"Pille, M. et al. Gene editing-based targeted integration for correction of Wiskott-Aldrich syndrome. Mol. Ther. Methods Clin. Dev. 32, 101208 (2024).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"5270_CR328","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3389\/fbioe.2020.00817","volume":"8","author":"B He","year":"2020","unstructured":"He, B. et al. Assessing the impact of data preprocessing on analyzing next generation sequencing data. Front. Bioeng. Biotechnol. 8, 817 (2020).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"5270_CR329","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114810","volume":"43","author":"N Daga","year":"2024","unstructured":"Daga, N. et al. Integration of genetic and chromatin modification data pinpoints autoimmune-specific remodeling of enhancer landscape in CD4(+) T cells. Cell Rep. 43, 114810 (2024).","journal-title":"Cell Rep."},{"key":"5270_CR330","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17626-2","volume":"11","author":"R Rai","year":"2020","unstructured":"Rai, R. et al. Targeted gene correction of human hematopoietic stem cells for the treatment of Wiskott - Aldrich Syndrome. Nat. Commun. 11, 4034 (2020).","journal-title":"Nat. Commun."},{"key":"5270_CR331","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/978-1-0716-1979-7_20","volume":"2429","author":"N Devaraju","year":"2022","unstructured":"Devaraju, N., Rajendiran, V., Ravi, N. S. & Mohankumar, K. M. Genome engineering of hematopoietic stem cells using CRISPR\/Cas9 system. Methods Mol. Biol. 2429, 307\u2013331 (2022).","journal-title":"Methods Mol. Biol."},{"key":"5270_CR332","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.synbio.2018.09.004","volume":"3","author":"R Yao","year":"2018","unstructured":"Yao, R. et al. CRISPR-Cas9\/Cas12a biotechnology and application in bacteria. Synth. Syst. Biotechnol. 3, 135\u2013149 (2018).","journal-title":"Synth. Syst. Biotechnol."},{"key":"5270_CR333","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s12033-021-00422-8","volume":"64","author":"N Bharathkumar","year":"2022","unstructured":"Bharathkumar, N. et al. CRISPR\/Cas-based modifications for therapeutic applications: a review. Mol. Biotechnol. 64, 355\u2013372 (2022).","journal-title":"Mol. Biotechnol."},{"key":"5270_CR334","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00203-024-03962-0","volume":"206","author":"H Wu","year":"2024","unstructured":"Wu, H., Sun, Y., Wang, Y., Luo, L. & Song, Y. Advances in miniature CRISPR-Cas proteins and their applications in gene editing. Arch. Microbiol. 206, 231 (2024).","journal-title":"Arch. Microbiol."},{"key":"5270_CR335","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e24606","volume":"10","author":"A Mohammadian Farsani","year":"2024","unstructured":"Mohammadian Farsani, A. et al. Lipid nanoparticles: the game-changer in CRISPR-Cas9 genome editing. Heliyon 10, e24606 (2024).","journal-title":"Heliyon"},{"key":"5270_CR336","doi-asserted-by":"publisher","unstructured":"Whittaker, M. N. et al. Improved specificity and efficiency of in vivo adenine base editing therapies with hybrid guide RNAs. Preprint at https:\/\/doi.org\/10.1101\/2024.04.22.590531 (2025).","DOI":"10.1101\/2024.04.22.590531"},{"key":"5270_CR337","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/bs.ircmb.2022.04.010","volume":"372","author":"I G\u00f3mez-Aguado","year":"2022","unstructured":"G\u00f3mez-Aguado, I. et al. mRNA delivery technologies: toward clinical translation. Int. Rev. Cell Mol. Biol. 372, 207\u2013293 (2022).","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"5270_CR338","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1635475","volume":"13","author":"F Hu","year":"2025","unstructured":"Hu, F. et al. Innovation networks in the advanced medical equipment industry: supporting regional digital health systems from a local-national perspective. Front. Public Health 13, 1635475 (2025).","journal-title":"Front. Public Health"},{"key":"5270_CR339","doi-asserted-by":"crossref","unstructured":"Kruglova, N. & Shepelev, M. Increasing gene editing efficiency via CRISPR\/Cas9- or Cas12a-mediated knock-in in primary human T Cells. Biomedicines 12, 119 (2024).","DOI":"10.3390\/biomedicines12010119"},{"key":"5270_CR340","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58921-0","volume":"16","author":"G Zhang","year":"2025","unstructured":"Zhang, G. et al. TRAPT: a multi-stage fused deep learning framework for predicting transcriptional regulators based on large-scale epigenomic data. Nat. Commun. 16, 3611 (2025).","journal-title":"Nat. Commun."},{"key":"5270_CR341","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40290-022-00451-x","volume":"37","author":"A Bateman-House","year":"2023","unstructured":"Bateman-House, A., Shah, L. D., Escandon, R., McFadyen, A. & Hunt, C. Somatic gene therapy research in pediatric populations: ethical issues and guidance for operationalizing early phase trials. Pharm. Med. 37, 17\u201324 (2023).","journal-title":"Pharm. Med."},{"key":"5270_CR342","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.stemcr.2020.03.010","volume":"14","author":"EC Jonlin","year":"2020","unstructured":"Jonlin, E. C. Informed consent for human embryo genome editing. Stem Cell Rep 14, 530\u2013537 (2020).","journal-title":"Stem Cell Rep"},{"key":"5270_CR343","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/medethics-2019-105620","volume":"46","author":"B Cwik","year":"2020","unstructured":"Cwik, B. Intergenerational monitoring in clinical trials of germline gene editing. J. Med. Ethics 46, 183\u2013187 (2020).","journal-title":"J. Med. Ethics"},{"key":"5270_CR344","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/ejhg.2011.29","volume":"19","author":"K Hens","year":"2011","unstructured":"Hens, K., Cassiman, J. J., Nys, H. & Dierickx, K. Children, biobanks and the scope of parental consent. Eur. J. Hum. Genet 19, 735\u2013739 (2011).","journal-title":"Eur. J. Hum. Genet"},{"key":"5270_CR345","doi-asserted-by":"crossref","unstructured":"Hasanpour, S., Eagderi, S., Poorbagher, H. & Hasanpour, M. Maternal and zygotic activin signaling promotes adequate pattern and differentiation of mesoderm through regulation of pluripotency genes during zebrafish development. Int. J. Dev. Biol. Available from: http:\/\/europepmc.org\/abstract\/MED\/34549797. 65, 513\u2013522(2021).","DOI":"10.1387\/ijdb.210073se"},{"key":"5270_CR346","unstructured":"Hasanpour, M. et al. Cranio-cervical junction malignant extrarenal rhabdoid tumor: a case report. J. Pediatr. Perspect. Available from: https:\/\/jpp.mums.ac.ir\/article_21466.html. 10, 17192\u201317199 (2022)."},{"key":"5270_CR347","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1186\/s12967-024-05235-2","volume":"22","author":"M Qin","year":"2024","unstructured":"Qin, M., Deng, C., Wen, L., Luo, G. & Meng, Y. CRISPR-Cas and CRISPR-based screening system for precise gene editing and targeted cancer therapy. J. Transl. Med. 22, 516 (2024).","journal-title":"J. Transl. Med."},{"key":"5270_CR348","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202402630","volume":"34","author":"X Yang","year":"2024","unstructured":"Yang, X. et al. Exploring the potential and challenges of CRISPR delivery and therapeutics for genetic disease treatment. Adv. Funct. Mater. 34, 2402630 (2024).","journal-title":"Adv. Funct. Mater."},{"key":"5270_CR349","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102636","volume":"36","author":"N Kalter","year":"2025","unstructured":"Kalter, N. et al. Off-target effects in CRISPR-Cas genome editing for human therapeutics: Progress and challenges. Mol. Ther. Nucleic Acids 36, 102636 (2025).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"5270_CR350","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2025.10","volume":"27","author":"B Cetin","year":"2025","unstructured":"Cetin, B., Erendor, F., Eksi, Y. E., Sanlioglu, A. D. & Sanlioglu, S. Advancing CRISPR genome editing into gene therapy clinical trials: progress and future prospects. Expert Rev. Mol. Med. 27, e16 (2025).","journal-title":"Expert Rev. Mol. Med."},{"key":"5270_CR351","doi-asserted-by":"crossref","unstructured":"Ren, D., Fisson, S., Dalkara, D. & Ail, D. Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy. Pharmaceutics. 14, 1973 (2022).","DOI":"10.3390\/pharmaceutics14091973"},{"key":"5270_CR352","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1007\/s13346-023-01320-z","volume":"13","author":"F Sinclair","year":"2023","unstructured":"Sinclair, F., Begum, A. A., Dai, C. C., Toth, I. & Moyle, P. M. Recent advances in the delivery and applications of nonviral CRISPR\/Cas9 gene editing. Drug Deliv. Transl. Res. 13, 1500\u20131519 (2023).","journal-title":"Drug Deliv. Transl. Res."},{"key":"5270_CR353","doi-asserted-by":"publisher","DOI":"10.1002\/poc.4157","volume":"34","author":"M Rahimi","year":"2021","unstructured":"Rahimi, M. & Fattahi, A. Acidity enhancement of \u03b1-carbon of beta diketones via hydroxyl substituents: A density functional theory study. J. Phys. Org. Chem. 34, e4157 (2021).","journal-title":"J. Phys. Org. Chem."},{"key":"5270_CR354","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40264-025-01596-9","volume":"49","author":"E Youssef","year":"2026","unstructured":"Youssef, E., Weddle, K., Zimmerman, L. & Palmer, D. Pharmacovigilance in cell and gene therapy: evolving challenges in risk management and long-term follow-up. Drug Saf. 49, 27\u201353 (2026).","journal-title":"Drug Saf."},{"key":"5270_CR355","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","volume":"24","author":"E Haapaniemi","year":"2018","unstructured":"Haapaniemi, E., Botla, S., Persson, J., Schmierer, B. & Taipale, J. CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response. Nat. Med. 24, 927\u2013930 (2018).","journal-title":"Nat. Med."},{"key":"5270_CR356","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00011-020-01368-4","volume":"69","author":"L Tang","year":"2020","unstructured":"Tang, L. et al. The association between IL18, FOXP3 and IL13 genes polymorphisms and risk of allergic rhinitis: a meta-analysis. Inflamm. Res. 69, 911\u2013923 (2020).","journal-title":"Inflamm. Res."},{"key":"5270_CR357","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.omtn.2022.09.022","volume":"30","author":"C Happi Mbakam","year":"2022","unstructured":"Happi Mbakam, C. et al. Prime editing optimized RTT permits the correction of the c.8713C>T mutation in DMD gene. Mol. Ther. Nucleic Acids 30, 272\u2013285 (2022).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"5270_CR358","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29339-9","volume":"13","author":"X Li","year":"2022","unstructured":"Li, X. et al. Highly efficient prime editing by introducing same-sense mutations in pegRNA or stabilizing its structure. Nat. Commun. 13, 1669 (2022).","journal-title":"Nat. Commun."},{"key":"5270_CR359","doi-asserted-by":"crossref","unstructured":"Tearing up the traditional biotech playbook. Vol. 42, Nature biotechnology. United States; p. 1. (2024)","DOI":"10.1038\/s41587-023-02119-6"},{"key":"5270_CR360","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122685","volume":"348","author":"T Mohammadian Gol","year":"2024","unstructured":"Mohammadian Gol, T. et al. Gene therapy in pediatrics \u2013 Clinical studies and approved drugs (as of 2023). Life Sci. 348, 122685 (2024).","journal-title":"Life Sci."},{"key":"5270_CR361","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1038\/s41591-022-01906-z","volume":"28","author":"B Fu","year":"2022","unstructured":"Fu, B. et al. CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric \u03b2(0)\/\u03b2(0) transfusion-dependent \u03b2-thalassemia. Nat. Med. 28, 1573\u20131580 (2022).","journal-title":"Nat. Med."},{"key":"5270_CR362","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3390\/thalassrep13010006","volume":"13","author":"U Gamage","year":"2023","unstructured":"Gamage, U., Warnakulasuriya, K., Hansika, S. & Silva, G. N. CRISPR gene therapy: a promising one-time therapeutic approach for transfusion-dependent \u03b2-Thalassemia\u2014CRISPR-Cas9 gene editing for \u03b2-Thalassemia. Thalass Rep. 13, 51\u201369 (2023).","journal-title":"Thalass Rep."},{"key":"5270_CR363","doi-asserted-by":"publisher","unstructured":"FDA clears prime editors for testing in humans. Nat. Biotechnol. 42, 691. Available from: https:\/\/doi.org\/10.1038\/s41587-024-02264-6 (2024).","DOI":"10.1038\/s41587-024-02264-6"},{"key":"5270_CR364","unstructured":"Food US. Toxicity Risks of Adeno-associated Virus (AAV) Vectors for Gene Therapy (GT) (2021)."},{"key":"5270_CR365","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/gt.2014.109","volume":"22","author":"ML Hirsch","year":"2015","unstructured":"Hirsch, M. L. Adeno-associated virus inverted terminal repeats stimulate gene editing. Gene Ther. 22, 190\u2013195 (2015).","journal-title":"Gene Ther."},{"key":"5270_CR366","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1089\/hgtb.2019.276","volume":"30","author":"P Wilmott","year":"2019","unstructured":"Wilmott, P., Lisowski, L., Alexander, I. E. & Logan, G. J. A User\u2019s guide to the inverted terminal repeats of adeno-associated virus. Hum. Gene Ther. Methods 30, 206\u2013213 (2019).","journal-title":"Hum. Gene Ther. Methods"},{"key":"5270_CR367","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1038\/s41591-021-01522-3","volume":"27","author":"MS Keiser","year":"2021","unstructured":"Keiser, M. S. et al. Toxicity after AAV delivery of RNAi expression constructs into nonhuman primate brain. Nat. Med 27, 1982\u20131989 (2021).","journal-title":"Nat. Med"},{"key":"5270_CR368","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S0966-842X(03)00208-7","volume":"11","author":"R Noad","year":"2003","unstructured":"Noad, R. & Roy, P. Virus-like particles as immunogens. Trends Microbiol. 11, 438\u2013444 (2003).","journal-title":"Trends Microbiol."},{"key":"5270_CR369","doi-asserted-by":"crossref","unstructured":"Han, Z., Tan, C., Ai, J. & Zhu, Y. In vivo adeno-associated virus-mediated LDLR\/PCSK9 intervention for familial hypercholesterolemia. Genes Dis. 12, 101632 (2025).","DOI":"10.1016\/j.gendis.2025.101632"},{"key":"5270_CR370","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1016\/j.ymthe.2022.06.004","volume":"30","author":"DE Sabatino","year":"2022","unstructured":"Sabatino, D. E. et al. Evaluating the state of the science for adeno-associated virus integration: an integrated perspective. Mol. Ther. 30, 2646\u20132663 (2022).","journal-title":"Mol. Ther."},{"key":"5270_CR371","doi-asserted-by":"crossref","unstructured":"Brescia, M., Janssen, J. M., Liu, J. & Gon\u00e7alves, M. A. F. V. High-capacity adenoviral vectors permit robust and versatile testing of DMD gene repair tools and strategies in human cells. Cells. 9, 869 (2020).","DOI":"10.3390\/cells9040869"},{"key":"5270_CR372","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1089\/nat.2018.0721","volume":"28","author":"JA Kulkarni","year":"2018","unstructured":"Kulkarni, J. A., Cullis, P. R. & van der Meel, R. Lipid nanoparticles enabling gene therapies: from concepts to clinical utility. Nucleic Acid Ther. 28, 146\u2013157 (2018).","journal-title":"Nucleic Acid Ther."},{"key":"5270_CR373","doi-asserted-by":"crossref","unstructured":"Zar\u00e0, M. et al. Biology and role of extracellular vesicles (EVs) in the pathogenesis of thrombosis. Int. J. Mol. Sci. 20, 2840 (2019).","DOI":"10.3390\/ijms20112840"},{"key":"5270_CR374","doi-asserted-by":"crossref","unstructured":"Szatanek, R. et al. The methods of choice for extracellular vesicles (EVs) characterization. Int. J. Mol. Sci. 18, 1153 (2017).","DOI":"10.3390\/ijms18061153"},{"key":"5270_CR375","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/978-1-0716-4690-8_16","volume":"2952","author":"S Pandey","year":"2025","unstructured":"Pandey, S. et al. Artificial intelligence-based genome editing in CRISPR\/Cas9. Methods Mol. Biol. 2952, 273\u2013282 (2025).","journal-title":"Methods Mol. Biol."},{"key":"5270_CR376","doi-asserted-by":"publisher","DOI":"10.1016\/j.cobme.2023.100477","volume":"28","author":"JHC Fong","year":"2023","unstructured":"Fong, J. H. C. & Wong, A. S. L. Advancing CRISPR\/Cas gene editing with machine learning. Curr. Opin. Biomed. Eng. 28, 100477 (2023).","journal-title":"Curr. Opin. Biomed. Eng."},{"key":"5270_CR377","doi-asserted-by":"publisher","unstructured":"Saini, H. et al. Role of artificial intelligence tools in CRISPR-Cas9 genomic editing technique for precision agriculture. Ind. Biotechnol. 21, 228\u2013235. Available from: https:\/\/doi.org\/10.1089\/ind.2025.0007 (2025).","DOI":"10.1089\/ind.2025.0007"},{"key":"5270_CR378","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2024.109137","volume":"182","author":"A Boretti","year":"2024","unstructured":"Boretti, A. The transformative potential of AI-driven CRISPR-Cas9 genome editing to enhance CAR T-cell therapy. Comput. Biol. Med. 182, 109137 (2024).","journal-title":"Comput. Biol. Med."},{"key":"5270_CR379","doi-asserted-by":"crossref","unstructured":"Srivastav, A. K., Mishra, M. K., Lillard, J. W. J. & Singh, R. Transforming Pharmacogenomics and CRISPR gene editing with the power of artificial intelligence for precision medicine. Pharmaceutics. 17, 555 (2025).","DOI":"10.3390\/pharmaceutics17050555"},{"key":"5270_CR380","doi-asserted-by":"publisher","unstructured":"Naert, T. et al. Precise, predictable genome integrations by deep-learning-assisted design of microhomology-based templates. Nat. Biotechnol. Available from: https:\/\/doi.org\/10.1038\/s41587-025-02771-0 (2025).","DOI":"10.1038\/s41587-025-02771-0"},{"key":"5270_CR381","doi-asserted-by":"publisher","unstructured":"Qu, Y. et al. CRISPR-GPT for agentic automation of gene-editing experiments. Nat. Biomed. Eng. Available from: https:\/\/doi.org\/10.1038\/s41551-025-01463-z (2025).","DOI":"10.1038\/s41551-025-01463-z"},{"key":"5270_CR382","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/s43588-023-00569-1","volume":"3","author":"Z Zhang","year":"2023","unstructured":"Zhang, Z., Lamson, A. R., Shelley, M. & Troyanskaya, O. Interpretable neural architecture search and transfer learning for understanding CRISPR\u2013Cas9 off-target enzymatic reactions. Nat. Comput. Sci. 3, 1056\u20131066 (2023).","journal-title":"Nat. Comput. Sci."},{"key":"5270_CR383","doi-asserted-by":"crossref","unstructured":"Lee, M. Deep learning in CRISPR-Cas systems: a review of recent studies. Front. Bioeng. Biotechnol. Volume 11. Available from: https:\/\/www.frontiersin.org\/journals\/bioengineering-and-biotechnology\/articles\/10.3389\/fbioe.2023.1226182 (2023).","DOI":"10.3389\/fbioe.2023.1226182"},{"key":"5270_CR384","unstructured":"Ruffolo, J. A. et al. Design of highly functional genome editors by modeling the universe of CRISPR-Cas sequences. Preprint at Available from: https:\/\/www.biorxiv.org\/content\/early\/2024\/04\/22\/2024.04.22.590591 (2024)."},{"key":"5270_CR385","doi-asserted-by":"publisher","unstructured":"Qin, J., Wessels, H. H., Fernandez-Granda, C. & Hao, Y. Active learning for efficient discovery of optimal gene combinations in the combinatorial perturbation space. Preprint at https:\/\/doi.org\/10.48550\/arXiv.2411.12010 (2024).","DOI":"10.48550\/arXiv.2411.12010"}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05270-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05270-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05270-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T19:02:17Z","timestamp":1784314937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05270-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":385,"alternative-id":["5270"],"URL":"https:\/\/doi.org\/10.1038\/s41390-026-05270-3","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All authors agree to submit the manuscript for publications.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Ethics"}}]}}